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Dear Colleagues,
Management of comorbidities constitutes an important part of treatment in heart failure (HF). HF is a clinical 
syndrome where the incidence and prevalence gradually increase with age. Advanced age is associated with 
increased incidence rates of comorbidities such as hypertension, diabetes, coronary artery disease, hyper-
lipidemia, atrial fibrillation, chronic obstructive pulmonary disease, renal impairment, degenerative valvular 
disease, and sleep apnea. Registry studies indicate that only 4% of HF patients over 65 years of age are free 
of comorbidities while 40% have ≥5 comorbid conditions. The recently published data of Heart Failure Long 
Term Registry including 12,440 cases demonstrated presence of hypertension in 58% of the patients with 
HF, ischemic heart disease in 43%, atrial fibrillation in 37%, diabetes in 32%, renal dysfunction in 18% and 
chronic obstructive pulmonary disease in 14%. The rates are even higher among patients hospitalized due 
to acute HF. Comorbidities are more common in heart failure with preserved ejection fraction as the patients 
are older, and management of comorbidities presents the mainstay of treatment in these patients.
Comorbidities complicate symptomatic control in heart failure, interfere with quality of life, worsen the clinical 
course, and increasehospitalization rates as well as mortality. Furthermore, certain comorbidities such as 
renal dysfunction and chronic obstructive pulmonary disease also interfere with evidence based treatment 
of HF. Similarly, the clinical course of HF may be disrupted further due to some medications used for the 
treatment of comorbid conditions (calcium channel blockers, glitazones, NSAIDs, inhaled beta-mimetics, 
steroids etc.). Therefore, HF guidelines strongly emphasize the fact that adequate control and management 
of comorbidities is an essential aspect of HF treatment.
Iron deficiency and anemia are among the most commonly seen comorbidities in HF. Data obtained from 
studies indicate that approximately half of the patients with HF have iron deficiency and/or anemia. Histori-
cally, iron deficiency and anemia have been shown to be strongly associated with the severity and prognosis 
of HF, and since the evidence obtained in recent years indicate clinical benefits with relevant treatment in 
HF, the treatment of iron deficiency and anemia in HF has become a subject of interest. The clinical benefits 
demonstrated in small studies with erythropoiesis stimulating agents were not subsequently confirmed in 
major studies; furthermore, thromboembolic events were shown to be increased with these agents, leading 
to disappointment. However, although improved mortality has not been demonstrated, major studies on intra-
venous iron therapy have shown improvement in quality of life, NYHA class, 6-minute walking distance, peak 
oxygen consumption and HF hospitalization rates in patients with iron deficiency with or without anemia, 
making intravenous iron therapy a treatment target in HF. In 2016, the ESC guidelines on HF were the first to 
include intravenous iron administration as a standard recommendation for patients with HF.
This document prepared as a guide by professionals with knowledge and expertise in their fields provides a 
comprehensive discussion on iron deficiency and anemia in HF, and evaluates the relevant approaches for 
management and treatment in current clinical practice in light of the currently available evidence.
It is our hope that this document provided by the Heart Failure Working Group of Turkish Society of Cardiol-
ogy will serve as a useful guide for healthcare professionals.
Prof. Dr. Yüksel Çavuşoğlu, Fellow of the HFA, Fellow of the ESC 
Special Issue Editor
Former Chairperson of TSC Heart Failure Working Group (2012-2014)
Eskişehir Osmangazi University, Faculty of Medicine, Cardiology Department, Eskişehir
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Heart failure is an important community health problem. Preva-
lence and incidence of heart failure have continued to rise over the 
years. Despite recent advances in heart failure therapy, prognosis 
is still poor, rehospitalization rate is very high, and quality of life is 
worse. Comorbidities in heart failure have negative impact on clinical 
course of the disease, further impair prognosis, and add difficulties 
to treatment of clinical picture. Therefore, successful management 
of comorbidities is strongly recommended in addition to conventional 
therapy for heart failure. One of the most common comorbidities in 
heart failure is presence of iron deficiency and anemia. Current evi-
dence suggests that iron deficiency and anemia are more prevalent 
in patients with heart failure and reduced ejection fraction, as well as 
those with heart failure and preserved ejection fraction. Moreover, 
iron deficiency and anemia are referred to as independent predic-
tors for poor prognosis in heart failure. There is strong relationship 
between iron deficiency or anemia and severity of clinical status of 
heart failure. Over the last two decades, many clinical investigations 
have been conducted on clinical effectiveness of treatment of iron 
deficiency or anemia with oral iron, intravenous iron, and erythro-
poietin therapies. Studies with oral iron and erythropoietin therapies 
did not provide any clinical benefit and, in fact, these therapies have 
been shown to be associated with increase in adverse clinical out- 
comes. However, clinical trials in patients with iron deficiency in the 
presence or absence of anemia have demonstrated considerable 
clinical benefits of intravenous iron therapy, and based on these 
positive outcomes, iron deficiency has become target of therapy in 
management of heart failure. The present report assesses current 
approaches to iron deficiency and anemia in heart failure in light of 
recent evidence.
Keywords: Anemia; heart failure; iron deficiency.
ABSTRACT
Kalp yetersizliği, insidans ve prevalansı giderek artan önemli bir 
toplum sağlığı problemidir. Tedavide sağlanan ilerlemelere rağ-
men halen yaşam kalitesi düşük, hastaneye yatış oranları yüksek 
ve prognoz kötüdür. Kalp yetersizliğine eşlik eden hastalıklar kli-
nik seyri olumsuz etkilemekte, prognozu kötüleştirmekte, tedavi-
yi güçleştirmekte ve klinik tablonun kontrolünü zorlaştırmaktadır. 
Bu nedenle kalp yetersizliğine yönelik tedavi ile birlikte komorbid 
durumların tedavisi ve kontrolünün sağlanması önemle vurgulan-
maktadır. Kalp yetersizliğinde en sık rastlanan komorbid durumlar-
dan biri demir eksikliği ve anemidir. Mevcut veriler demir eksikliği 
ve aneminin hem düşük ejeksiyon fraksiyonlu hem de korunmuş 
ejeksiyon fraksiyonlu kalp yetersizliğinde yaygın olduğunu gös-
termektedir. Aynı zamanda kalp yetersizliğinde demir eksikliği ve 
anemi kötü prognoz için bağımsız prediktörler olarak bulunmak-
tadır. Ayrıca demir eksikliği ve aneminin klinik tablonun ciddiyeti 
ile güçlü bir ilişkisi söz konusudur. Son yıllarda komorbid durum 
olarak demir eksikliği ve/veya aneminin eritropoietin, oral demir 
veya intravenöz demir ile tedavisiyle kalp yetersizliğinde klinik 
yarar sağlanıp sağlanamayacağına ilişkin çalışmalar yapılmıştır. 
Eritropoietin ve oral demir ile yapılan çalışmalarda beklenen klinik 
yararlar sağlanamamış ve istenmeyen olaylarda artış gözlenmiş-
tir. Anemi olsun olmasın demir eksikliği bulunan kalp yetersizliği 
olgularında intravenöz demir tedavisi ile yapılan çalışmalarda mor-
talitede olmasa bile klinik sonuçlarda anlamlı yararların gösteril-
mesi kalp yetersizliğinde demir eksikliğini tedavi hedefi konumuna 
getirmiştir. Rehber niteliğinde hazırlanan bu belgenin amacı, kalp 
yetersizliğinde demir eksikliği ve anemiye yaklaşımı güncel kanıt-
lar eşliğinde değerlendirmektir.
Anahtar sözcükler: Anemi; kalp yetersizliği; demir eksikliği.
ÖZET
1.0 INTRODUCTION – Yüksel Çavuşoğlu
Heart failure (HF) is a clinical syndrome accom-
panied by comorbidities. The most commonly seen 
comorbid conditions include hypertension, coronary 
artery disease, chronic renal impairment, diabetes, 
chronic obstructive pulmonary disease, and respira-
tory sleep apnea. In recent years, increasing evidence 
have shown that iron deficiency and anemia are com-
mon in patients with HF with reduced ejection frac-
tion (HFrEF), HF with preserved ejection fraction 
(HFpEF) and in patients with acute HF. Discovery 
of the notion that iron deficiency and anemia are in-
dependent predictors of poor prognosis in HF led to 
increased interest regarding iron deficiency and ane-
mia in HF. The clinical benefits shown with treat-
ment for iron deficiency and anemia have brought a 
new dimension to this field by drawing attention of 
healthcare professionals. This document prepared to 
serve as a guide aims to evaluate the questions, con-
cerns and solutions likely to be encountered during 
everyday clinical practice regarding iron deficiency 
and anemia in HF based on the currently available 
evidence.
2.0 DEFINITION, POTENTIAL CAUSES, 
CLINICAL FEATURES – Yüksel Çavuşoğlu
2.1 What is the definition and importance of 
iron deficiency and anemia in heart failure?
Iron deficiency and anemia are among the most 
commonly seen comorbidities in heart failure. When 
defined according to World Health Organization 
criteria (hemoglobin <13 g/dL in men, <12 g/dL in 
women), anemia is present approximately in 1/3 of 
patients with HF. Anemia prevalence was reported as 
37.2% in a meta-analysis including 153,180 patients 
with HF.[1] This rate decreases to nearly 20% in clini-
cal studies on HF as patients with severe anemia and 
serious renal dysfunction are excluded from the clini-
cal studies; however, a prevalence of anemia of up to 
49% is observed in patients hospitalized due toacute 
decompensated HF.[2] These figures indicate that ane-
mia is a significant problem in HF. Anemia has beco-
me an important consideration and a treatment target 
in HF during the last 2 decades upon being associated 
with the severity of HF as well as serving as a prog-
nostic indicator.
The prevalence of iron deficiency with or witho-
ut anemia is reported to be 37%-61% in HF.[3] These 
figures indicate a higher incidence rate for iron defi-
ciency with or without anemia compared to the pre-
valence of anemia. Furthermore, iron deficiency has 
been identified as a marker of poor prognosis regard-
less of the anemia status.[4] Mortality is increased by 
4-fold in patients with iron deficiency with or without 
anemia compared to those without iron deficiency.[5] 
These findings indicate that iron deficiency is a stron-
ger prognostic marker than anemia. In recent years, 
studies on intravenous (IV) iron therapy have shown 
significant benefits in clinical outcomes (improved 
quality of life, improvement in NYHA class, increase 
in 6-minute walking distance, increased peak oxygen 
consumption, decreased HF hospitalization) if not in 
mortality, highlighting the importance of iron defi-
ciency treatment in HF, followed by the inclusion in 
ESC guidelines on HF as a target of treatment for the 
first time in 2016.[5,6]
2.2 Are iron deficiency and anemia different 
conditions in heart failure?
Iron deficiency in HF is defined as ferritin levels 
<100 µg/L or transferrin saturation (TSAT) <20% if 
the ferritin level is 100-299 µg/L.[5,6] On the other 
hand, anemia is defined as hemoglobin values <13 g/
dL in men and <12 g/dL in women as per the World 
Health Organization criteria. Presence of anemia is 
not necessarily required for iron deficiency. In other 
words, iron deficiency may be present without ane-
mia. Iron deficiency was found in 37% of all pati-
ents included in a prospective observational series 
of 546 patients with HFrEF while the rate was 57% 
and 32% among anemic and non-anemic patients, 
respectively.[4] The analysis of the largest internati-
onal patient pool to date (n=1506, patients HFrEF 
and HFpEF) has revealed iron deficiency in 50% of 
all HF patients while this rate was reported as 61% 
in anemic HF patients and 46% in non-anemic HF 
patients.[7] These findings indicate that a significant 
portion of HF patients without anemia are in fact 
iron-deficient.
2.3 What are the causes and potential
mechanisms of iron deficiency and anemia
in heart failure? 
The causes and potential mechanisms of iron de-
ficiency and anemia in HF are considered complex 
and multi-factorial. The most commonly highlighted 
causes include inflammatory activation, malnutriti-
Turk Kardiyol Dern Ars2
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on, renal impairment, hemodilution, diabetes, impa-
ired bone marrow function, receiving an angiotensin 
converting enzyme inhibitor (ACEi) or angiotensin 
receptor blocker (ARB), and occult bleeding in the 
gastrointestinal system (GIS)[8–10] (Table 1).
Inadequate nutrition, decreased iron absorption 
and occult blood loss in GIS are the first scenarios 
to consider regarding the causes and potential mec-
hanisms of iron deficiency. Conditions such as in-
testinal edema, loss of appetite and cachexia result 
in impaired iron intake due to inadequate nutrition, 
particularly with the progression of HF.[8–10] As the 
underlying cause in 2/3 of patients with HF is co-
ronary artery disease requiring co-administration of 
aspirin and other antiplatelet agents, such treatment 
is known to be associated with chronic blood loss in 
GIS.
Increased inflammatory activation in heart failu-
re leads to elevated hepcidin levels in the liver.[2,3,8–10] 
Hepcidin is a protein which blocks intestinal iron 
intake by means of ferroportin inhibition. Hepcidin 
production is stimulated by cytokines such as interle-
ukin (IL)-6 and IL-1 and tumor necrosis factor-alpha 
(TNF-alpha). Increased hepcidin reduces intestinal 
iron intake. Furthermore, hepcidin decreases the relea-
se of iron by macrophages, thereby leading to reduced 
levels of available iron. Elevated pro-inflammatory 
cytokines (TNF-alpha, IL-6, IL-1, IL-18) do not only 
increase hepcidin levels but also decrease renal eryt-
hropoietin secretion, suppress erythropoietin activity 
in the bone marrow and lead to reduced iron reservo-
irs in heart failure.[2,3,8–10]
Renal dysfunction is present in 20-25% of pati-
ents with heart failure and contributes to anemia de-
velopment by reducing erythropoietin production in 
the kidney. Anemia risk is increased by 3-fold in HF 
patients with GFR <60 mL/min/1.73 m2.[11] ACEi/
ARBs constitute the mainstay of treatment in HF and 
contribute to anemia development by suppressing 
erythroid progenitor cell development and by redu-
cing the levels and blocking the function of angio-
tensin, which normally induces erythropoietin pro-
duction.[8–10]
While reported evidence demonstrate that the 
congestion and hypervolemia observed in HF pati-
ents result in dilutional anemia,[12] it should also be 
noted that hemodilution may be involved in anemia 
development mechanisms, particularly in patients 
hospitalized for acute decompensated HF and patients 
with advanced HF. In fact, anemia prevalence is re-
ported to be higher among patients hospitalized for 
acute decompensated HF compared to HF patients in 
the outpatient setting, with anemic parameters which 
may return to normal upon resolving the congestion.
[12,13] For diabetic patients, the glycosylation-related 
damage on erythropoietin-producing cells in the kid-
ney is thought to contribute to anemia in HF patients 
by reducing erythropoietin production. Indeed, lower 
hemoglobin levels are reported among diabetic pati-
ents compared to non-diabetics.[10]
2.4 What are the clinical features associated 
with iron deficiency and anemia in heart
failure?
Anemic HF patients are often older, female, cac-
hectic subjects with advanced HF presentation, renal 
dysfunction and concurrent diabetes (Table 2). The-
re is a close, well-established association between 
Table 1. Mechanisms of iron deficiency and anemia in 
heart failure
Increased inflammatory cytokines
Increased hepcidin
Renal impairment and decreased erythropoietin production
Receiving ACEi/ARB
Malnutrition
Occult bleeding in the gastrointestinal tract
Hemodilution
Diabetes
Impaired bone marrow function
Table 2. Clinical features associated with iron 
deficiency and anemia in heart failure
Advanced age
Female gender
Low body mass index
NYHA III-IV
Increased natriuretic peptide
Elevated C-reactive protein
Renal dysfunction
Diabetes
Peripheral edema
High-dose diuretic use
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dition to signs and symptoms of HF.[13,16-18] On the 
other hand, some analyses either did not provide a 
distinction between HFrEF and HFpEF or included 
patients with HFrEF as well patients with HFpEF to 
compare the frequency of anemia and iron deficiency 
between the groups.[7,14] As data on the incidence of 
anemia and iron deficiency in HFpEF will be discus-
sed in the next section, the information provided in 
this section covers the prevalence and incidence in 
HFrEF.
Because there is no consensus on the definition of 
anemia, different studies have reported different inci-
dences for anemia. A commonly used definition is the 
one provided by World Health Organization (WHO), 
which defines anemia as hemoglobin (Hb) level of 
less than 13 g/dL in men and 12 g/dL in women.[19] 
Although this definition is commonly employed in the 
current practice, it is criticized for being outdated and 
being based on insufficient and low-quality data.[20] 
The analyses based on this WHO definition reported 
an anemia prevalence of 16%-49%.[15-18,15,21] Anemia 
prevalence varied between 10% to 17% in studies 
conducted with more conservative criteria (Hb ≤12 
g/ dL for men, ≤11 g/dL for women).[11,16,22] Findings 
of a recent, multi-center, prospective observational 
study, which was conducted in Europe and included 
mainly HFrEF patients, has reported the prevalence 
of anemia as 28%.[7] The incidence of new-onset ane-
mia in HF patients without previous anemia was 9.6% 
in SOLVD (Studies on Left Ventricular Dysfunction), 
14.2% in COMET (Carvedilol or Metoprolol Europe-
an Trial) and 16.9% in Val-HEFT (Valsartan in Heart 
Failure Trial).[2] Because all of these studies used he-
moglobin criteria to define anemia, the proportion of 
anemias resulting from a true reduction in erythrocyte 
mass remains unclear. A study reported that dilution 
caused by fluid overload may be responsible for up 
to 46% of anemias, even in HF patients without cli-
nical fluid overload.[12] Therefore, it should be noted 
that the figures on the prevalence and incidence of 
anemia may be influenced by additional factors such 
as decompensation status as well as the definition of 
anemia.
Most of the studies reported a higher prevalence of 
anemia among patients with iron deficiency compared 
to those with normal iron levels. Klip et al. reported 
the prevalence of iron deficiency as 35% in anemic 
patients versus only 22% in patients without anemia 
(p<0.001).[7] A study conducted in 2010 showed the 
the severity of HF and anemia.[2–4] Anemia incidence 
rates are known to increase with worsening NYHA 
classes.[2–4] Female gender, elevated BNP and plasma 
C-reactive protein levels are closely associated with 
anemia.[4] Furthermore, anemia is also associated 
with clinical characteristics of advanced HF such as 
peripheral edema, increased creatinine, low GFR and 
potassium levels, use of high-dose diuretics, hypo-
natremia and low body mass index.[2,11] While anemia 
prevalence is somewhat higher among middle-aged 
women compared to men, higher prevalence rates are 
observed in men with advanced age.[2,11]
Chronic renal disease is anindependent and strong 
predictor of anemia. Anemia levels worsen propor-
tionally with the degree of renal dysfunction.[2,11] In 
patients with GFR <60 mL/min/1.73 m2, a 0.29 gr/dL 
drop in hemoglobin level is reported with each 10 mL 
decrease in GFR.[14] Additionally, cachexia and ane-
mia are linked as an indicator of clinical worsening in 
HF, and increasing anemia rates are seen with decre-
ased body mass index. Anemia prevalence is higher 
among diabetic patients compared to non-diabetics.[15] 
Furthermore, the frequency of diabetes is reported to 
be higher in anemic subjects compared to non-anemic 
patients.
Prevalence of anemia is reported to be simi-
lar among patients with HFrEF and HFpEF. The 
CHARM study found anemia in 27% of the patients 
with HFpEF and in 25% of patients with HFrEF.[14] 
Anemia prevalence is known to increase with worse-
ning diastolic dysfunction. However, it should be ta-
ken into account that the age factor and greater num-
ber of comorbidities in HFpEF may also contribute to 
higher prevalence in this group. A weak correlation is 
reported between EF and hemoglobin levels.[16]
3.0 PREVALENCE – Tolga Sinan Güvenç
3.1 How common are iron deficiency and
anemia in heart failure?
As with all other diseases, the prevalence and 
incidence of anemia and iron deficiency in chronic 
HF eventually depends on how these three disorders 
(HF, anemia and iron deficiency) were defined. The 
available data often show the extent of anemia and 
iron deficiency in HFrEF as majority of retrospecti-
ve analyses on observational studies and randomized 
controlled trials included a left ventricular ejection 
fraction of less than 35% or 40% as a criteria, in ad-
incidence of iron deficiency as 57% among anemic 
patients compared to an incidence of only 32% among 
non-anemic subjects.[4] As discussed below, the dif-
ferences in definition had a major effect on different 
results regarding to the incidence of iron deficiency 
among anemic HF patients. For instance, incidence 
of iron deficiency was 78% in a study where iron de-
ficiency was defined only on the basis of TSAT, while 
this incidence was as low as 20% when serum ferritin 
level was also included in the criteria in addition to 
TSAT.[23]
Investigations conducted only using peripheral 
blood samples may not adequately reflect the inciden-
ce of iron deficiency. An elegant study conducted by 
Nanas et al. showed that iron deficiency in bone mar-
row was present in 73% of the patients in HFrEF but 
without iron deficiency in peripheral blood samples.
[24] While this study had suggested a much higher in-
cidence for iron deficiency in HF patients compared 
to previous reports, the fact that anemia is normocy-
tic even in patients with iron deficiency highlights the 
notion that iron deficiency is not the only etiological 
factor.[2,15] An analysis investigating the different etio-
logical factors of anemia in HF patients failed to find 
a relevant factor in 57% of the 148 patients and these 
patients were classified as anemia of chronic disease 
based on laboratory findings.[25] However, iron defici-
ency was diagnosed using peripheral blood samples 
in this latter analysis. The fact that the chronic inflam-
mation caused by HF leads to functional iron defici-
ency suggests that majority of these patients may in 
fact have multi-factorial anemia.
Iron deficiency should be considered as a comorbi-
dity alone, even if it does not lead to anemia. As is the 
case with HF and anemia, the frequency of iron defi-
ciency also depends on the definition. Studies based 
solely on “absolute” iron deficiency found the frequ-
ency of iron deficiency as 6%-21% in HF.[26]However, 
the cut-off value of ferritin to define iron deficiency 
used in these studies was 30 mg/dL, which was inapp-
ropriate for the diagnosis of iron deficiency in patients 
with chronic inflammatory conditions.[27]
Increased levels of IL-6 and other inflammatory 
cytokines interfere with iron absorption and transport 
of the readily available iron to the bone marrow, resul-
ting in absolute as well as functional iron deficiency 
in HF.[28] A definition including both the absolute and 
functional components of iron deficiency would be 
serum ferritin ≤100 µg/L or serum ferritin level 100–
299 µg/L with serum TSAT ≤20%. This definition was 
used in randomized controlled trials such as FAIR-HF 
(Ferinject Assessment in Patients With IRon Defici-
ency and Chronic Heart Failure) and CONFIRM-HF 
(Ferric CarboxymaltOse evaluatioN on perFormance 
in patients with IRon deficiency in coMbination with 
chronic Heart Failure).[29,30] These studies have de-
monstrated the benefit of intravenous iron therapy in 
patients with absolute or functional iron deficiency.
[29,30] Therefore, the functional form should also be ta-
ken into account when reporting the frequency of iron 
deficiency.
A large-scale prevalence study conducted using 
the aforementioned definitions reported the frequency 
of iron deficiency as 37% while another study found 
a rate of 50%.[7,12] In other words, when functional 
iron deficiency is included in the estimation, iron de-
ficiency is seen in approximately 1/3 to 1/2 of all HF 
patients.
Studies on the prevalence of anemia and iron defi-
ciency in heart failure are summarized in Table 3.
3.2 Do iron deficiency and anemia occur in
heart failure with preserved ejection fraction?
Patients classified as heart failure with preserved 
ejection fraction (HFpEF) are older and have more 
comorbidities than those with HFrEF. Because both 
of these conditions increase the prevalence of ane-
mia, one may expect anemia to be more common in 
HFpEF compared to HFrEF. However, a limited num-
ber of comparative studies did not found substantial 
difference between these two patients groups in terms 
of anemia frequency. A retrospective analysis of the 
CHARM (The Candesartan in Heart Failure: Assess-
ment of Reduction in Mortality and Morbidity) studi-
es which included both HFpEF and HFrEF patients, 
anemia was somewhat more common with HFpEF 
compared to HFrEF; however, the difference was not 
significant (27% vs 25%).[14] The analysis also showed 
that mean EF was higher in patients with anemia ver-
sus non-anemic patients (39 vs 38%, p=0.049) and EF 
was a standalone predictor of anemia.[14] The analysis 
conducted with the more recent data from SENIORS 
(The Study of the Effects of Nebivolol Intervention 
on OUtcomes and Rehospitalization in Seniors with 
Heart Failure) showed no difference between patients 
with EF <35% and >35% in terms of anemia preva-
lence (19.0% vs 18.7%, p=0.87).[31]
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patients is at least as high as that in HFrEF patients 
and population-based studies indicate that anemia 
prevalence may be even higher than HFrEF. Taking 
into account the other studies except the ARIC analy-
sis which included decompensated patients, one may 
conclude that anemia prevalence ranges from 18.7% 
to 58% among HFpEF patients.
Majority of the studies on iron deficiency eit-
her included only HFrEF patients or all HF patients 
were included in the analyses without distinguishing 
HFpEF/HFrEF. Therefore, there is insufficient data on 
the prevalence of iron deficiency in HFpEF. In two stu-
dies with considerably small sample sizesand included 
only HFpEF patients, iron deficiency prevalence was 
found to be 57% and 70%. One of these studies exc-
luded anemic patients while the latter included both 
anemic and non-anemic patients.[37,38] In an analysis of 
approximately 1500 patients including HFpEF as well 
as HFrEF cases, frequency of iron deficiency was re-
ported to be 50%; however, this study did not provide 
the frequency of iron deficiency for each group.[7] Whi-
le the currently available data suggest that iron defici-
ency prevalence is similar or higher in HFrEF patients 
compared to HFpEF, further studies are warranted to 
identify the prevalence more accurately.
Information regarding the studies on iron defi-
ciency and anemia prevalence in HFpEF patients is 
summarized in Table 4.
Both studies used the WHO criteria to define ane-
mia.
On the other hand, both analyses employed data 
from randomized clinical trials. Observational stu-
dies including real-life data have indicated that ane-
mia prevalence may be higher in HFpEF patients. 
Two small studies investigating the prevalence of 
anemia reported a prevalence of 45%-55%.[32,33] A 
study conducted in Olmsted region found a higher 
anemia prevalence (58%) among HFpEF patients in 
the prospective arm while anemia prevalence was 
also high (48%) in the HFrEF group.[34] An analysis 
on the data obtained from the prospective and ob-
servational ARIC (Atherosclerosis Risk in Commu-
nities) study showed a higher anemia prevalence in 
HFpEF patients compared to HFrEF among subjects 
with acute decompensation (71.2% vs 69.5%); ho-
wever, the total anemia prevalence was considerably 
higher (70%) compared to other HF studies.[35] In a 
sub-analysis of OPTIMIZE-HF (Organized Program 
to Initiate Lifesaving Treatment in Hospitalized Pati-
ents With Heart Failure), which was an observational 
registry study in hospitalized patients, mean Hb was 
significantly lower among HFrEF patients compared 
to HFpEF.[36]The high prevalence of anemia obser-
ved in this study could be secondary to the presence 
of additional risk factors for anemia in decompensa-
ted patients.
In conclusion, the frequency of anemia in HFpEF 
Table 3. Studies on the prevalence and incidence of anemia and iron deficiency in patients with chronic heart failure
Study subject Frequency Notes References
Anemia prevalence in HF patients 11%–49% Closely linked with the definition 11,13,15-17,
  of anemia 21,22
Anemia incidence in non-anemic 9.6%–16.9% Data obtained from randomized 2
HF patients  controlled trials
Prevalence of “absolute” iron 6%–21% Considered only iron, ferritin 26
deficiency in HF patients  or transferrin saturation
Prevalence of absolute or functional 37%–50% Ferritin <100 µg/L or Ferritin 4,7
iron deficiency in HF patients  100-299 µg/L with TSAT ≤20%
Prevalence of iron deficiency 20%–73% The highest rate was reported in patients 4,7,23,24
in anemic HF patients  for whom iron reservoirs were evaluated
  with bone marrow biopsy
Prevalence of iron deficiency 22%–32% Ferritin <100 µg/L or Ferritin 4,7
in non-anemic HF patients  100-299 µg/L with TSAT ≤20%
HF: Chronic heart failure; TSAT: Transferrin saturation.
3.3 What is the prevalence of iron deficiency 
and anemia in patients with acute heart failure?
Before discussing the prevalence in patients with 
acute heart failure (AHF), it should be noted that the 
anemia in some patients may not be true anemia, but 
may rather develop secondary to decompensation. 
As mentioned previously under a previous title, in 
37 anemic patients with HF assessed for transplanta-
tion who had no clinical fluid overload, normal red 
blood cell mass and presence of “pseudoanemia” se-
condary to plasma expansion were found in 46%.[2] 
Similarly, a study by Abramov et al. showed that all 
patients with HFrEF had plasma volume expansion 
and only 57% of them had true red blood cell defici-
ency. Interestingly, plasma expansion was responsib-
le for only a minority (12%) of anemias in patients 
with HFpEF in this study, i.e. the “true” prevalence 
of anemia in HFpEF may be higher than HFrEF.[39] 
Since plasma volume expansion may be expected to 
be higher in patients with decompensated heart fai-
lure requiring hospitalization, prevalence of anemia 
for AHF in observational studies is generally higher 
from that in chronic HF. Anemia is of prognostic im-
portance in these patients regardless of an associa-
tion with pseudoanemia; however, whether anemia 
requires specific therapy in these patients remains 
unclear.[11]
In a registry study of 1960 patients hospitalized for 
acute heart failure, prevalence of anemia was found 
to be 57% using WHO criteria.[40] In a sub-analysis 
of the OPTIMIZE-HF registry, Hb was ≤12.1 g/dL 
in 51.2% of the patients.[41] Also in the ADHERE 
study that evaluated data of more than 100,000 pa-
tients, prevalence of anemia was found to be 53%.
[42] Contrary to other studies, a prevalence of 14.7% 
was reported in EHFS-II (Euro Heart Failure Survey 
II) registry in which frequency of anemia was hig-
her in patients with decompensated chronic HF com-
pared to those with de novo AHF (16.8%–11.3%, 
p<0.001).[43] Data from the observational TAK-TIK 
registry study that included 558 patients from Turkey 
reported mean Hb value as 12.4±2.1 g/dL in patients 
hospitalized for AHF.[44] No secondary analysis was 
performed for the presence of anemia in this study. 
However, a mean Hb value of 12.4 g/dL suggests that 
the prevalence might be close to 50%.[44] Analysis of 
the previously mentioned ARIC study revealed ane-
mia prevalence as 70% in patients with AHF, and the 
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Table 4. Studies on the prevalence of anemia and iron deficiency in patients with heart failure and preserved ejection 
fraction
Study subject Frequency Notes Source
Data on anemia prevalence obtained
from RCTs on HFpEF
 CHARM 27% Higher anemia prevalence in  14
   HFpEF compared to HFrEF
 SENIORS 18.7% No difference versus HFrEF 31
Data from retrospective analyses or
observational registries on HFpEF
 Brucks et al.  45%  32
 Tehrani et al.  55%  33
 Dunlay et al.  58% Significantly higher (48%)  34
   compared to HFrEF
 Caughey et al. 71.2% Included acute decompensated patients 35
Iron deficiency prevalence in HFpEF patients 
 Kasner et al. 57% Included 26 HFpEF patients 37
 Nuñes et al. 70% Included 40 HFpEF patients 38
HFpEF: Heart failure with preserved ejection fraction; RCT: Randomized controlled trial; CHARM: The Candesartan in Heart Failure: Assessment of Re-
duction in Mortality and Morbidity; SENIORS: The Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart 
Failure.
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despite the different definition of iron deficiency as 
it remains unknown whether the standard definition 
used in FAIR-HF and CONFIRM-HF studies applies 
to AHF patients.[28,29,46–48] Iron deficiency prevalence 
was 70% and 74% respectively in two studies, one 
of which defined iron deficiency as serum ferritin le-
vel under <100 µg/L and the other defined it as se-
rum ferritin level between 100–299 µg/L and serum 
transferrin ≤20%. Prevalence of absolute iron defi-
ciency, on the other hand, is lower (48.2%).[49,50] As 
previously mentioned it is still discussed whether it 
is appropriate to use these criteria in AHF patients 
or whether they are related to prognosis.[51] As serum 
hepcidin/soluble transferrin receptor or absolute iron 
deficiency may be closely related to prognosis in 
AHF patients,[46,50] 37–49% of the AHF patients seem 
to have iron deficiency (approximately 1/3 to 1/2 of 
patients).
4.0 PROGNOSIS – Hakan Altay
4.1 Do iron deficiency and anemia influence the 
prognosis in heart failure?
Studies have shown that anemia is associated with 
the severity of HF and also predictive of high risk for 
both death and hospitalizations.[24,52,53] These studies 
show that anemia increases both short- and long-term 
mortality by 1.5–2 fold independentof the other clini-
cal variables. Prognosis of HF gets worse especially 
when there is concomitant cardiorenal syndrome and 
anemia. In a study with HFrEF patients, Scrutinie et 
al. reported that HF, renal failure and anemia consti-
tute a fatal combination which they called the “cardi-
orenal anemia syndrome”.[54]
The impact of anemia on the prognosis was also 
studied in well-known large HF trials. In the SOLVD 
study, a 10% increase in mortality was observed for 
each 1 g/dL decrease in hemoglobin levels.[55] In Val-
HEFT, it was demonstrated that the presence of ane-
mia created a 20% increase in the risk of mortality 
and morbidity.[16] The same study showed that it was 
the change in hemoglobin levels over time that influ-
enced prognosis rather than the overall hemoglobin 
values. In ValHEFT, new onset anemia was reported 
in 16.9% of the patients and there was a closer rela-
tionship between the change in hemoglobin levels 
over 12 months and late clinical endpoints compared 
to BNP, glomerular filtration rate (GFR) and even 
baseline hemoglobin level. It has also been shown 
prevalence was found to be high both in HFrEF and 
HFpEF groups.[35] In summary, with the exception of 
EHFS-II registry, prevalence of anemia was found to 
be between 50-70% in majority of the studies, indica-
ting a higher prevalence in AHF compared to chronic 
HF. 
As indicated by the EHFS-II data, prevalence of 
anemia may be lower in patients with de novo AHF 
in whom the degree of plasma volume expansion is 
currently mild.[43] Studies investigating the prevalence 
of anemia in AHF are shown in Figure 1.
While it has been shown that treatment of iron de-
ficiency with IV iron preparations reduces the com-
bined endpoint of mortality and hospitalization in 
patients with chronic HF, large studies have recently 
evaluated the frequency of iron deficiency in AHF. In 
a study by Rovellini et al. in 2012 involving 200 pa-
tients hospitalized for AHF, the incidence of anemia 
thought to be associated with absolute iron deficiency 
was 6.9%. However, serum iron levels were low and 
TSAT was high in patients with both microcytic and 
normocytic anemia.[45]
In another study by Jankowska et al. in which 
iron deficiency was defined by low hepcidin and high 
soluble transferrin receptor concentration, the pre-
valence of iron deficiency was reported to be 37%.
[46] In this study, it was particularly meaningful that 
iron deficiency was seen in one third of the patients 
Figure 1. Studies investigating the prevalence of anemia in 
patients with acute heart failure. Values found for anemia 
prevalence in patients with acute heart failure in various 
observational registry studies. EHFS-II, Euro Heart Failure 
Survey II;[43] OPTIMIZE-HF, Organized Program to Initiate 
Lifesaving Treatment in Hospitalized Patients With Heart 
Failure;[41] ADHERE, Acute Decompensated Heart Failure 
National Registry;[42] ARIC, Atherosclerosis Risk in Com-
munities.[35]
100
90
80
70
60
50
40
30
20
10
0
EHFS-II OPTIMIZE-HF ADHERE ARIC
Prevalence
that improvement of anemia using intravenous 
iron preparations prevents adverse clinical events, 
reinforcing the importance of anemia in HF prog-
nosis.[56]
Despite abundant evidence demonstrating the re-
lationship between anemia and poor prognosis in HF, 
the mechanisms that describe this worsening of HF 
in anemic patients are not clearly understood. These 
mechanisms are both complicated and multifactorial. 
Factors that explain the poor prognostic relationship 
between anemia and HF include advanced age, higher 
prevalence of comorbidities and renal failure in par-
ticular, increased neurohormonal activation, chronic 
inflammation, and reduced free radical scavenging 
capacity. It is also possible that anemia is associated 
with poor prognosis due to severe underlying myocar-
dial dysfunction.
Previously, the relationship between iron defici-
ency and HF was considered only in the context of 
anemia. However, after it was understood that a re-
duced hemoglobin level is the end result of a long 
process initiating with the depletion of ironstores, 
researchers have begun to focus on the relationship 
between iron deficiency without anemia and HF prog-
nosis. Studies investigating the contribution of iron 
deficiency to HF prognosis have revealed conflicting 
results. Jankowska et al. showed in their study that 
reduced iron levels without anemia is a common fin-
ding in HF, and has negative effects on prognosis.[4] 
On the other hand, Parikh et al. showed that there is 
no association between iron deficiency and all-cause 
or cardiovascular mortality in patients with HF.[57] In 
this study, however, diagnosis of HF was established 
by asking patients and the severity of HF was not 
evaluated based on NYHA functional class and NT-
proBNP levels. A large international study investiga-
ting patients with both HFrEF and HFpEF demons-
trated that iron deficiency is common in HF (50%) 
and shows correlation with NYHA functional class 
as well as NT-proBNP levels both of which relates 
to severity of HF, and predicts mortality independent 
of other established factors (including anemia).[7] The 
prognostic importance of iron deficiency in HF has 
also been demonstrated in studies showing improved 
prognosis after treatment with IV iron preparationsin 
patients with heart failure accompanied by iron defici-
ency. Indeed, Anker et al. showed the favorable effect 
of IV iron treatment on prognosis in chronic HF both 
in patients with and without anemia.[29]
 Studies showing the relationship between iron de-
ficiency and prognosis in HF are summarized in Table 
5. Although it is not clear whether anemia is the cau-
se or the consequence of HF, it can clearly be stated 
that anemia has a strong relationship with the severity 
of HF and adverse events. In addition, it would not 
be erroneous to think that, iron deficiency is associa-
ted with high mortality and hospitalization as well as 
progression of HF regardless of the presence of ane-
mia in HF and may be a more valuable prognostic tool 
than anemia in this context.
4.2 Do iron deficiency and anemia influence
quality of life in heart failure? 
Besides being associated with advanced chronic 
HF, iron deficiency also impairs the energy metabo-
lism of both myocardium and skeletal muscles by re-
ducing hemoglobin and decreasing oxygen transport. 
Furthermore, it may cause a reduction in myoglobin 
levels even in the absence of anemia, resulting in 
dysfunction of peripheral muscle tissues. Taking these 
effects into consideration, iron deficiency is thought 
to reduce exercise capacity, leading to decreased qu-
ality of life in HF regardless of presence or absence 
of anemia. Indeed, both CONFIRM-HF and FAIR-HF 
studies have shown an increase in 6-minute walking 
distance equivalent to that obtained with other medici-
nes with proven benefits in addition to improvement in 
NYHA functional class and quality of life in patients 
with HF receiving IV iron treatment.[29,30] Jankowska et 
al. published a meta-analysis of studies comparing the 
effects of IV iron treatment in patients with HFrEF and 
found improved exercise time, NYHA functional class 
and quality of life with IV iron treatment.[58] In additi-
on, they found that IV iron treatment provided these 
beneficial effects independent of anemia, emphasizing 
the importance of iron deficiency for exercise capacity 
and quality of life.
The hemoglobin in the blood plays an important 
role in supplying increased oxygen demand of both 
the myocardium and skeletal muscles during exercise. 
Since normal physiologic reserve is low in patients 
with HF, the decrease in hemoglobin level cannot be 
compensated, and results in reduced exercise capacity. 
As a matter of fact, studies confirmed a correlation 
between anemia and NYHA functional class in HF.[59]
 Anemia is particularly observed in elderly HF pa-
tients with serious symptoms, low body mass index 
and cachexia, accompanied by chronic renal failure. 
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Therefore, the association between anemia and impai-
red quality of life is not unexpected in HF. Since there 
is a correlation between dilutional anemia and clinical 
congestion, anemia indicates symptomatic patients 
with worse outcomes.[12]
Anemia may lead to deterioration of symptoms 
and decreased functional capacity by enhancing direct 
neurohormonal activation and decreasing the bioava-
ilability of nitric oxide (NO).[60] Studies investigating 
the influence of improving anemia by erythropoie-
tic therapy on functional capacity and quality of life 
have reported conflicting results. Exercise capacity 
was found to increase with erythropoietin treatment 
Table 5. Studies investigating the relationship of iron deficiency and anemia with prognosis in heart failure
Study Year Number  Inclusion criteria Primary endpoint Results
  of patients
Kosiborod et al. 2003 2281 Patients >65 years  Mortality Anemia was found to be 
   old hospitalized Re-hospitalization associated both with death 
   for HFz  and re-hospitalization
Mozaffarian et al. 2003 1130 NYHA class III and  Mortality Anemia was found to be an
(PRAISE)   IV, HFrEF   independent risk factor for
   (EF<30%)  mortality. Each 1% decrease
     in Htc resulted in an 11%
     increase in death.
Ahmad et al. 1991 2569 Chronic HFrEF  Survival according Each 1 g/dL decrease in Hb 
(SOLVD subgroup   (EF<35%) to GFR and was associated with a 10% 
analysis)    Htc levels increase in death.
Anand et al.  2005 5010 NYHA class II, III  Mortality and  Anemia was shown to increase 
(VaLHEFT   and IV, HFrEF  hospitalizations the risk of mortality and morbidity
subgroup   (EF<40%) Hb change at 12  by 20%.
analysis)    months and its  The relationship between
    impact on clinical mortality and new onset change
    events in Hb at 12 months was shown to
     be even greater than the
     relationship with baseline anemia.
Jankowska et al. 2010 546 Mild-severe HFrEF  All-cause death or  ID (not anemia) was shown to be
   (EF<35%) heart associated with increased death 
    transplantation or heart transplantation
Okonko et al. 2011 157 Patients with  Mortality ID was shown to be associated
   HFrEF (EF<35%) Exercise with exercise capacity and
    capacity increased mortality regardless
     of Hb.
Parikh et al. 2011 574 Patients with self- All-cause and CV No relationship between ID and 
   reported HF mortality mortality was reported.
Klip et al. 2013 1506 Patients with  Mortality ID was shown to be related with 
   HFrEF (EF<45%)  NYHA functional  both NYHA class and NT-proBNP 
   and HFpEF class levels and with mortality
     regardless of anemia.
ID: Iron deficiency; HFrEF: Heart failure with reduced ejection fraction; EF: Ejection fraction; Hb: Hemoglobin; Htc: Hematocrit, CV: Cardiovascular; HF: 
Heart failure; HFpEF: Heart failure with preserved ejection fraction; NYHA: New York Heart Association.
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5.0 CLINICAL DIAGNOSIS
Mehmet Birhan Yılmaz
5.1 Which iron deficiency and anemia
parameters should be routinely checked in
patients with heart failure?
Also being indicated in various guidelines (Table 
6), hemoglobin is recommended routinely in all pati-
ents newly diagnosed with HF according to the two 
most recent HF guidelines.[6,65] Anemia is an impor-
tant parameter that determines the treatment modality 
in HF. Investigating iron deficiency parameters is also 
considered as a weak recommendation during the ini-
tial diagnosis of chronic HF. In addition, checking fer-
ritin and transferrin saturation may be required rather 
than recommended in an HF patient with at least one 
hospitalization due to iron deficiency as iron deficiency 
is associated with poorer functional capacity and prog-
nosis and may occur even in the absence of anemia.[66]
Complete blood count is among the routine tests for 
the diagnosis of acute and chronic HF. It may also be 
measured periodically during the follow-up. Ferritin 
and TSAT should be checked if hemoglobin levels are 
found to be lower than 15 g/dL at any time point in 
HFrEF patients with a certain extent of cardiac load 
and NYHA II-III symptoms (although inclusion crite-
rion in CONFIRM-HF was <15 g/dL, benefit was more 
pronounced with <12 g/dL in the subgroup analysis). 
TSAT is a percentage value estimated by serum iron/
total iron binding capacity. Total iron binding capacity 
in patients with anemia and moderate to severe HF.[61] 
Another study reported that no increase was observed 
in functional capacity by treating anemia with dar-
bepoetin alfa in 41 patients with anemia and HF.[62] 
In a recent study, darbepoetin provided no benefit on 
the clinical outcome in patients with mild to modera-
te anemia and systolic HF.[63] The STAMINA HeFT 
study conducted in patients with HFrEF and anemia 
evaluated the effect of darbepoetin on exercise du-
ration, NYHA functional class and quality of life.[64] 
In this study, despite a significant increase in hemog-
lobin levels, darbepoetin did not provide any benefit 
on exercise duration, NYHA class and quality of life. 
The fact that no benefit was seen in terms of exercise 
and quality of life with erythropoietin despite the cor-
rection of anemia has been partially explained by the 
undesired effects of these drugs such as hypertension 
and thrombosis.
It is obvious that iron deficiency and anemia has 
an unfavorable impact on quality of life in HF. Results 
of the studies carried out to date indicate the need to 
target iron deficiency rather than hemoglobin levels 
in order to improve exercise capacity and quality of 
life. Indeed, European Heart Association 2016 Heart 
Failure guidelines recommend treatment with IV iron 
preparations with an indication level of class IIa in 
the presence of iron deficiency in order to improve 
exercise capacity and quality of life in symptomatic 
systolic HF.[6]
Table 6. Recommendations for anemia testing according to various guidelines
 Complete blood count Recommendation
  level
2008 ESC HF Complete blood count is a routine in the diagnostic investigation of HF None
2012 ESC HF Complete blood count is recommended in the diagnostic investigation Class 1C
 of HF, differential diagnosis of acute HF, and determination of prognosis
 Ferritin and TIBC are recommended for treatment and determination of prognosis Class 1 C
2016 ESC HF Hemoglobin and WBC are recommended for eligibility for specific treatment  Class 1C
 in newly diagnosed HF and determination of modifiable causes, and complete 
 blood count is recommended for the differential diagnosis of HF
 Ferritin and TSAT (TSAT=TIBC) are recommended for eligibility for specific Class 1C
 treatment in newly diagnosed HF and determination of modifiable causes
2010 HFSA Complete blood count is routinely recommended in the diagnostic investigation Evidence level B
 of chronic HF. Complete blood count is routine in acute HF. (chronic)
2013 ACCF/AHA HF Complete blood count is recommended in the diagnostic investigation of HF Class 1C
TSAT: Transferrin saturation; TIBC: Total iron binding capacity; WBC: White blood cells.
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is a measure of all proteins (majority of which is trans-
ferrin) that can bind to serum iron derived from the sum 
of unsaturated iron binding capacity and serum iron.
In patients diagnosed with anemia, evaluation of 
vitamin B12 and folate levels, occult blood test in the 
stool and peripheral smear are recommended as well 
as bone marrow biopsy if required for the diagnostic 
algorithms and etiologic differential diagnosis. At this 
point, particularly elevated RDW (red cell distributi-
on width) levels and microcytic structure in periphe-
ral smear are signals indicating iron deficiency.
5.2 Which criteria should the diagnosis be
based on for iron deficiency and anemia in
heart failure?
Definition of anemia according to World Health 
Organization is hemoglobin level below 13 g/dL for 
males over 15 years of age and below 12 g/dL for fe-
males over 15 years who are not pregnant. Anemia is 
a common condition among inpatients. Standard tests 
should be requested for the differential diagnosis of 
anemia for all patients with anemia.[67]
On the other hand, isolated iron deficiency does 
not mean anemia. Iron deficiency may occur in chro-
nic inflammatory diseases in which only iron reservo-
irs are diminished or iron utilization is impaired, or in 
skeletal muscle dysfunction with or without anemia. 
Sole iron deficiency is associated with poor prognosis 
in HF even in the absence of anemia.[68]
The criteria recommended for the diagnosis of iron 
deficiency in the presence or absence of anemia ac-
cording to 2016 European HF guidelines are presen-
ted in Table 7.[6]
5.3 What do absolute and functional iron
deficiencies refer to? How is the diagnostic
differentiationestablished?
Iron deficiency is considered in two types, namely 
absolute or functional. Absolute iron deficiency indi-
cates diminished iron reservoirs in the body due to 
insufficient iron intake, impaired GIS absorption or 
chronic blood loss.[69] Functional iron deficiency in-
dicates impaired iron absorption and utilization pos-
sibly due to increased hepcidin production and related 
inhibition of the iron carrier, ferroportin.[70]
Diagnosis of iron deficiency is complicated in pa-
tients with heart failure. The standard threshold of 
iron deficiency defined as ferritin <30µg/L offers an 
acceptable sensitivity and specificity. However, this 
threshold does not apply to chronic diseases such as 
HF since ferritin is also an acute phase reactant.[66]
5.4 What is the role of hepcidin and bone
marrow biopsy in diagnosis? Which patient, 
and when?
Dietary iron is reduced to Fe2+ by the duodenal 
cytochrome B in the lumen of duodenum and pro-
ximal jejunum. This is the region where iron enters 
enterocytes through the divalent metal transporter-1 
(DMT-1).[71] Subsequently, the iron is released into the 
circulation by ferroportin located in the basal-lateral 
walls of enterocytes. In the circulation, iron is conver-
ted into Fe3+ by hephaestin and then binds to trans-
ferrin in the plasma.[71] Transferrin receptor-1 expres-
sing cells uptake the transferrin-iron complex. Iron is 
stored in the liver, spleen and bone marrow as ferritin.
Hepcidin is a small peptide released by the liver 
to regulate iron homeostasis.[70] It binds to ferroportin 
and degrades this receptor, leading to the inhibition 
of iron absorption. As a result, iron accumulates in 
the enterocytes and is then eliminated by the shed-
ding of intestinal cells.[46] This indicates that oral iron 
treatment is not expected to work in iron deficiency 
with high hepcidin levels. Likewise, neutral results 
were reported in the IRONOUT study which evalu-
ated the effect of oral iron treatment in patients with 
HFrEF and was published last year.
Since ferroportin is also found in the macropha-
ges of the reticulo-endothelial system, hepcidin traps 
iron within RES cells, thereby reducing utilizable 
iron.[46] Hepatic expression of hepcidin is decreased 
in iron deficiency and increased in iron overload or 
inflammatory diseases like heart failure.[66]
Bone marrow biopsy or aspiration is among the 
final steps in the differential diagnosis of anemia and 
provides insight about the production of blood cells. 
It also plays a role in the differential diagnosis of 
more serious diseases (e.g. leukemia). It is not requ-
ired for the diagnosis of iron deficiency except for 
very serious conditions refractory to treatment or for 
the confirmation of response to treatment.[72]
Table 7. Criteria established for the diagnosis of iron 
deficiency in 2016 European heart failure guidelines
Absolute iron deficiency Serum ferritin <100 µg/L
Functional iron deficiency Serum ferritin 100-299 µg/L  
 and transferrin saturation <20%
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iron increases the risk of infection by impairing the 
functions of T cells and neutrophils although iron is 
required for healthy immune response.[79] Jankows-
ka et al. carried out a meta-analysis of five randomi-
zed controlled studies investigating the effects of IV 
iron treatment in patients with systolic heart failure 
and found that IV iron treatment improved NYHA 
class, increased the 6-minute walking distance and 
decreased the risk of the composite endpoint of all-
cause death and cardiovascular hospitalization as 
well as the composite endpoint of cardiovascular 
death and hospitalization due to worsening of heart 
failure.[80]
Another treatment method for iron deficiency is 
to use erythropoiesis-stimulating agents. However, 
studies have reported that using erythropoiesis-sti-
mulating agents alone offers no benefit in reducing 
mortality and hospitalization in patients with HF, and 
increases thromboembolic events. Therefore, they are 
not recommended for the treatment of iron deficiency 
in HF.[81]
Since blood transfusion has side effects including 
immunosuppression which increases the risk of infec-
tion, sensitization to HLA antigens and iron overlo-
ad, it is considered in the acute treatment of serious 
anemia rather than the long-term treatment of chronic 
anemia.[82]
6.2 Does treatment for iron deficiency and
anemia provide any clinical benefit?
Despite the advances in the treatment of heart fa-
ilure, restriction of daily activities particularly due 
to dyspnea and fatigue impact life style and increase 
morbidity in many patients. Several mechanisms re-
gardless of hemodynamic dysfunction are involved in 
the reduced exercise capacity in patients with HF. The 
leading mechanisms in this context are oxygen con-
sumption and insufficient oxygen supply.[74,83]
Iron plays a role in oxygen uptake and trans-
fer through hemoglobin, in oxygen storing through 
myoglobin, and in oxygen metabolism through oxi-
dative enzymes and mitochondrial respiratory chain 
proteins, all of which contain iron in their structure, 
and also in erythropoiesis.[83]
The iron content of myocardium is shown to dec-
rease in patients with HF, which is speculated to play 
a possible role in impaired systolic functions.[73,81]
Since energy production of myocardium and oxy-
6.0 TREATMENT OPTIONS AND CLINICAL 
BENEFIT – Nesligül Yıldırım
6.1 What are the treatment options for iron
deficiency and anemia?
Oral iron salts such as ferrous sulfate are frequ-
ently used in patients with iron deficiency due to 
convenience and low cost; however, they are not the 
first choice in HF because of frequent gastrointestinal 
side effects, reduced gastrointestinal absorption due 
to food and drug interactions, further limitation of 
absorption because of the intestinal mucosal edema 
particularly in patients with HF and the slow onset of 
effect.[73,74] In a recent retrospective study, however, 
it was shown that oral iron treatment may enhance 
iron reservoirs similar to IV iron treatment in pati-
ents with HF.[75] The IRONOUT-HF study investiga-
ted the effects of oral iron polysaccharide treatment 
on exercise capacity compared to placebo in patients 
with functional iron deficiency in HF.[76] According 
to the results presented at AHA 2016, oral iron treat-
ment has a mild effect on filling iron reservoirs and 
does not improve peak exercise capacity. It appears 
that questions on which HF patients may respond 
better to oral iron treatment and what sort of benefits 
oral treatment may offer will be further clarified in 
the future.
Intravenous iron treatment has drawn the attenti-
on of investigators owing to the absence of absorp-
tion problems and faster onset of effect compared to 
oral iron treatment. Iron sucrose, iron dextran, ferric 
gluconate and ferric carboxymaltose are frequently 
used IV iron preparations shown to exert various ef-
fects in experimental models. However, the clinical 
trial data comparing these agents are very limited.
[73] Elevated markers of oxidative stress and inflam-
mation, development of hypotension, and impaired 
renal and hepatic functions were observed in ani-
mals treated with iron dextran and ferric gluconate 
compared to those given ferric carboxymaltose and 
iron sucrose.[77,78] IV iron dextran is contraindicated 
since IV iron complexes containing dextran ligands 
may rarely have a risk of triggering anaphylactic re-
actions. Although rarely, iron preparations free of 
dextran also carry a risk of causing hypersensitivity 
reactions.[73]
Another important consideration regarding IV 
iron treatment is paying attention not to administer 
the treatment during an active infection as excessive 
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gen utilization of skeletal muscles during exercise are 
impaired in the pathophysiology of HF, treating iron 
deficiency would be expected to contribute favorably 
to the treatment of heart failure.[73,81,84]
Several studies in recent years have shown that 
treating iron deficiency with IV iron preparations in 
patients with chronic HF may have positive effects 
on functional capacity and quality of life.[30,56,73,81,84] 
As a matter of fact, Jankowska et al. carried out a 
meta-analysis of five randomized controlled studies 
investigating the effects of IV iron treatment in pa-
tients with HFrEF and found that IV iron treatment 
improves NYHA class (–0.54 class, 95% CI –0.87 to 
–0.21, p=0.001), increases the 6-minute walking dis-
tance (+31 m, 95% CI 18–43, p<0.0001), and imp-
roves quality of life (Kansas City Cardiomyopathy 
Questionnaire (KCCQ) score: +5.5 points, 95% CI 
2.8–8.3, p<0.0001; European Quality of Life–5 Di-
mensions (EQ-5D) score: +4.1 points, 95% CI 0.8–
7.3, p=0.01; Minnesota Living With Heart Failure 
Questionnaire (MLHFQ) score: −19 points, 95% CI 
–23 to −16, p<0.0001; Patient Global Assessment 
(PGA): +0.70 points, 95% CI 0.31–1.09, p=0.004). 
Moreover, they observed these positive effects on 
exercise capacity, quality of life and symptoms in 
both anemic and non-anemic patients with iron de-
ficiency.[58] The details of the studies included in the 
meta-analysis by Jankowska et al. are presented in 
Table 8.
6.3 Does treatment for iron deficiency and
anemia affect mortality?
In several studies performed to date, presence of 
iron deficiency in patients with HF has been shown 
to be closely associated with mortality regardless of 
the seriousness of heart failure and the presence of 
anemia.[79]
However, answers are not equally clear regarding 
the effect of correcting iron deficiency on mortality. 
Among subjects with heart failure and anemia in the 
FAIR-HF study, no difference was detected between 
the group receiving IV iron treatment and the group 
Table 8. Comparison of characteristics of the studies investigating the clinical effects of intravenous iron treatment
 Toblli et al. FERRIC-HF FAIR-HF IRON-HF CONFIRM-HF
 (n=40) (n=35) (n=459) (n=16) (n=301)
IV iron  Iron sucrose Iron sucrose Ferric  Iron sucrose Ferric
preparation   carboxymaltose  carboxymaltose
Administration 200 mg/week -Correction phase:  -Correction phase: 200 mg/week -Correction phase:
 Treatment  200 mg/week (until  200 mg/week Treatment  500-2000 mg
 duration 5 weeks ferritin >500 μg/L) -Maintenance  duration -Maintenance
  -Maintenance  phase: 200 mg  5 weeks phase: 500 mg
  phase: 200 mg every 4 weeks  Maximum treatment 
  every 4 weeks Maximum treatment   duration 36 weeks
  Total treatment  duration 24 weeks
  duration 16 weeks 
Follow-up 5 months post- 2 weeks post- Up to 24-26 Up to 3 months Up to 52 weeks
 treatment treatment weeks
NYHA class Improvement Improvement Improvement – Improvement
6-minute  No appropriate data – Increased – Increased
walking distance for meta-analysis
Quality of life Improvement Improvement Improvement – Improvement
LVEF Increased No difference  – – –
  between groups
NTproBNP Decreased – – – –
LVEF: Left ventricular ejection fraction; Hb: Hemoglobin; TSAT: Transferrin saturation; CrCl: Creatinine clearance; peak VO2: Peak O2 consumption; NYHA 
Class: New York Heart Association class; NT-proBNP: N-terminal pro-B-type natriuretic peptide.
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failure (OR 0.39, 95% CI 0.24–0.63, p=0.0001).
[30,56,79,83–85] On the other hand, no effect was detected 
on all-cause mortality or cardiovascular mortality. 
Comparison of characteristics of the studies inclu-
ded in the meta-analysis by Jankowska et al. is pre-
sented in Table 9.
7.0 CLINICAL STUDIES AND GUIDELINE 
RECOMMENDATIONS ON TREATMENT 
Ahmet Temizhan
7.1 Is treatment necessary in non-anemic iron 
deficiency?
Iron deficiency and anemia do not have the same 
meaning but refer to conditions with similar conse-
quences. Iron deficiency has been found despite the 
absence of anemia in approximately 46% of the pa-
tients with low EF and stable HF.[7] The iron-contai-
ning oxygen transport proteins in red blood cells are 
one of the most important structures of hemoglobin, 
the levels of which determine the decision of anemia. 
These iron containing proteins play a very critical role 
receiving placebo in terms of death due to cardiovas-
cular causes, death due to worsening of HF, and hos-
pitalization or death due to any cardiovascular cause 
while only the rate of first hospitalization due to any 
cardiovascular cause was found to be significantly 
lower in the group receiving IV iron treatment.[83] Si-
milarly, no difference was found between the groups 
regarding death due to cardiovascular causes and 
death due to worsening of HF in the CONFIRM-
HF study whereas hospitalizations due to worsening 
of HF were seen with a significantly lower rate in 
the group receiving IV iron treatment.[30] Currently, 
large studies evaluating the effect of IV iron treat-
ment on mortality are limited to CONFIRM-HF and 
FAIR-HF. However, Jankowska et al. evaluated the 
data from 5 randomized controlled studies in this fi-
eld by means of a meta-analysis and found that IV 
iron treatment decreased the risk of the composite 
endpoint of all-cause death or cardiovascular hospi-
talization (OR 0.44, 95% CI 0.30–0.64, p<0.0001) 
as well as the composite endpoint of cardiovascular 
death or hospitalization due to worsening of heart 
Table 9. Comparison of characteristics of the studies included in the meta-analysis by Jankowska et al. evaluating 
the effects of intravenous iron treatment on mortality
 Toblli et al. FERRIC-HF FAIR-HF IRON-HF CONFIRM-HF
All-cause death Data not included Data not included  No difference  Data not included  No difference 
 in meta-analysis in meta-analysis between groups in meta-analysis between groups
CV death – – No difference  – No difference
   between groups  between groups
All-cause death  – – No difference  – No differenceor 
CV    between groups  between groups
hospitalization
CV death or  – Data not included  No difference  – Decreased in the 
hospitalization due  in meta-analysis between groups  group receiving 
to worsening HF     intravenous iron
     treatment 
HF hospitalization Data not included Data not included  No difference  – Decreased in the 
 in meta-analysis in meta-analysis between groups  group
     intravenous 
     iron treatment
First hospitalization – – Decreased in the  – –
due to any CV    group receiving 
cause   intravenous iron 
   treatment
LVEF: Left ventricular ejection fraction; Hb: Hemoglobin; TSAT: Transferrin saturation; CrCl: Creatinine clearance; peak VO2: Peak O2 consumption; CV: 
Cardiovascular; HF: Heart failure.
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in vital cellular functions including oxygen storage 
(myoglobin) and energy production. 
Similar to that seen in anemia, exercise capacity 
and maximal oxygen consumption decreases when 
iron deficiency develops in humans without any 
drop in hemoglobin values.[86,87] Iron deficiency is 
frequently seen in HF and it causes skeletal muscle 
dysfunction and abnormal energy metabolism wit-
hout causing anemia as is the case in other chronic 
diseases,[69] resulting in increased symptoms as well 
as poor prognosis. Therefore, it would not be wrong 
to expect the treatment of iron deficiency to be inde-
pendent from anemia since its negative effects also 
appear to be independent from anemia. Three studies 
supporting this expectation are FERRIC-HF (Ferric 
Iron Sucrose in Heart Failure),[84] FAIR-HF (Ferin-
ject Assessment in Patients with Iron Deficiency and 
Chronic Heart Failure),[88] and CONFIRM-HF (Ferric 
CarboxymaltOse evaluation on perFormance in pati-
ents with IRon deficiency in coMbination with chro-
nic Heart Failure).[30] Findings of these three studies 
are consistent with each other and show that, regard-
less of anemia, IV iron treatment is a safe treatment 
which increases exercise capacity (quantitatively with 
the 6-minute walking distance[30] and pVO2/kg[84]), 
relieves symptoms, improves NYHA functional class 
and quality of life with an onset of effect as rapid as 
within 1 month,[88] and reduces hospital admissions 
and worsening of HF over one year.[30] Therefore, the-
se results indicate that treatment with IV iron should 
be considered in patients with a NYHA functional 
class of II-IV and HFrEF (left ventricular EF ≤45%) 
when serum ferritin level is <100 µg/L or serum fer-
ritin level is 100-299 µg/L with TSAT <20%, even in 
the absence of anemia.
7.2 What are the key messages of large
clinical studies on the treatment of iron
deficiency and anemia?
Lack of efficacy with erythropoietin treatment in 
chronic HF patients with anemia has directed the ap-
proaches towards iron deficiency as the focus of new 
investigations. Important studies have been published 
regarding the efficacy of IV iron treatment in HF pa-
tients with or without anemia during the last decade. 
Among the studies discussed herein, those other than 
FAIR-HF[29] (number of patients >450) and CON-
FIRM-HF[30] (number of patients >300) have evaluat-
ed a limited number of subjects; however, their contri-
bution in the context of methodology and results have 
been generally accepted. Detailed information about 
these studies is presented in Table 10 and 11. 
Toblli JE et al.[56] started the journey basically from 
the frequent co-existence of iron deficiency anemia, 
chronic HF and chronic renal failure. They investi-
gated the effects of IV iron treatment without erythro-
poietin on the problems caused by anemia in these pa-
tients. The study showed that hemoglobin, ferritin and 
TSAT values were increased with IV iron treatment. 
Furthermore, the most striking findings were, the im-
provements observed on left ventricular EF, NYHA 
functional class, exercise capacity, renal functions 
and quality of life. Interestingly, clinical improvement 
was associated with the improvement in iron param-
eters rather than the increase in hemoglobin levels. 
Although this study does not provide insight on the 
iron deficiency not accompanied by anemia, it is still 
considered an important study demonstrating that IV 
iron treatment is an important choice in patients with 
HF accompanied by chronic renal disease and anemia.
The FERRIC-HF study[84] showed that IV iron re-
placement increases exercise capacity and improves 
symptoms particularly in anemic HF patients with 
iron deficiency. The results were also not negative in 
patients without anemia. Despite not being statisti-
cally significant, a trend towards improvement was 
observed in these parameters. As seen in the study 
by Toblli et al.,[56] clinical improvement was associ-
ated with improved iron parameters and not with the 
increase in hemoglobin values. Despite the limited 
number of subjects, the evaluation of exercise capacity 
with a quantitative method such as pVO2/kg is among 
the properties that make FERRIC-HF a valuable study.
The FAIR-HF study has the highest number of sub-
jects among the studies investigating IV iron replace-
ment.[29] FAIR-HF revealed 4 key messages: 1- In 
case there is iron deficiency in symptomatic but stable 
patients with HF, IV replacement treatment with fer-
ric carboxymaltose improves symptoms, increases 
physical performance and quality of life, regardless 
of the presence of anemia. This finding indicates that 
iron deficiency is a better treatment target than ane-
mia. 2- Clinically beneficial effects occur within a 
short period, i.e. at 4 weeks of treatment. 3- Routinely 
investigating iron deficiency in symptomatic patients 
with HF may be an appropriate approach. 4- Results 
regarding clinical benefit are valid for patients with 
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a hemoglobin level <13.5 g/dL. This study provided 
no information regarding IV iron replacement for pa-
tients with hemoglobin levels higher than this value.
The most important characteristic of the IRON-HF 
study[85] is that it compared the efficacy of IV and oral 
iron treatment in chronic HF patients with anemia as-
sociated with iron deficiency. Despite the recovery of 
anemia in both replacement approaches, functional 
capacity was increased only in patients receiving IV 
iron treatment. The finding of no improvement in pa-
tients receiving oral therapy supports that the oral iron 
replacement approach frequently prescribed in outpa-
tient follow-up is in fact not a favorable option.
CONFIRM-HF is the most recent and one of the 
most important studies guiding treatment approaches 
for iron deficiency in European Heart Failure guide-
lines together with FAIR-HF.[30] The characteristics of 
CONFIRM-HF which distinguish this study from oth-
ers may be summarized as follows: 1- A simpler and 
more applicable iron replacement protocol has been 
developed using ferric carboxymaltose, 2- It provid-
ed a long-term evaluation for both the primary end-
point, i.e. 6 minute walking distance over 24 weeks 
and the second endpoints, i.e. NYHA functional class, 
patient’s global assessment and quality of life ques-
tionnaires over 52 weeks, and 3- Clinically solid end-
points including mortality and morbidity in the con-
text of secondary endpoints were also analyzed:
- All hospitalizations, all hospitalizations due to 
cardiovascular causes, hospitalization due to 
worsening of heart failure
- Time to first hospitalization due to any cause, 
time to first hospitalization due to any cardio-
vascular cause, and time to first hospitalization 
due to worsening of heart failure
 - Time to all-cause death, time to any cardiovas-
cular death, and time to death resulting from 
worsening of heart failure
At the end of the study, significant improvements 
were achieved in symptoms, functional capacity, 
quality of life and hospitalizations due to worsening 
of HF for over one year in symptomatic HF patients 
with iron deficiency receiving IV ferric carboxymalt-
ose treatment for 36 weeks. CONFIRM-HF provided 
hints indicating that iron treatment may reduce clini-
cal morbidity/mortality outcomes even if the findings 
are not too powerful owing to the fact that this study 
was not primarily designed for endpoints related to 
mortality and morbidity.
7.3 What do heart failure guidelines
recommend regarding the treatment of iron
deficiency and anemia?
The recommendation that takes into consideration 
the most detailed and recent studies has been included 
in 2016 European Heart Failure guidelines. Unlike the 
Table 11. Baseline characteristics of patients included in important studies on iron treatment in chronic heart failure 
patients with iron deficiency
Study Baseline characteristics*
 Age (y) Male  Ischemic NT-ProBNP LVEF NYHA Hb Anemia Ferritin TSAT
  (%) HF (%) (pg/mL) (%) sınıfı (g/dL) (%) (µg/L) 
Toblli
2007[56] 76±7 VY 63 256±125 31±4 2.9 10.3±0.6 100 73±30 20±1
FERRIC-HF
20084 64±14 28 74 VY 30±7 2.5 12.6±1.2 50 62±37 20±8
FAIR-HF
2009[29] 68±10 54 80 VY 32±6 2.8 11.9±1.3 65 53±55 18±13
IRON-HF
2013[85] 67±8 33 22 VY 25±9 VY 11.2±0.6 100 185±146 19±10
CONFIRM-HF
2014[30] 69±10 47 83 2511±5006 37±8 2.5 12.4±1.41 53 57±48 20±18
*Values in the treatment arm. Hb: Hemoglobin; LVEF: Left ventricular ejection fraction; HF: Heart failure; NYHA: New York Heart Association; TSAT: Transfer-
rin saturation; ND: No data.
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ents with HFrEF, the composite endpoint of all-cause 
death and cardiovascular hospitalization was reduced 
by 56% among subjects receiving IV iron treatment 
(n=509) compared to the control group (n=342) (OR 
0.44, 95% CI 0.30–0.64, p<0.0001).[58] In evaluation 
of individual components of the composite endpoint, 
no effect was observed on all-cause or cardiovascular 
death. On the other hand, the number of reported de-
aths were only 20 (4%) in the active treatment group 
and 19 (6%) in the control group, with a relatively 
short duration of follow-up.
 The effects of IV iron treatment other than the 
effects on major clinical endpoints have been asses-
sedin various studies. In the FAIR-HF study investi-
gating renal functions, estimated glomerular filtration 
rate (eGFR) at 24 weeks was increased by 2.98±1.44 
mL/min/1.73 m2 in patients treated with IV ferric car-
boxymaltose compared to placebo (p=0.039), and this 
effect remained the same between patients with baseli-
ne eGFR values below or higher than 60mL/min/1.73 
m2.[92] The effect on NT-proBNP and C-reactive protein 
was investigated in the study by Toblli et al.[56] in which 
IV iron sucrose was used in patients with renal failure 
(creatinine clearance <90 mL/min) and significant re-
ductions were observed in both markers at six months 
compared to placebo. In another study by the same 
team which investigated echocardiographic changes, 
significant decreases were observed in left ventricular 
systolic and diastolic diameters with a 6.6% absolute 
increase in ejection fraction in the active treatment gro-
up.[93] The increase in ejection fraction has also been 
assessed in other studies which reported a2% increase 
in 12 weeks as in the study by Gaber et al.[94] and 8% in 
6 weeks in the study by Núñez et al.[95]
The effects of IV iron preparations on clinical end-
points and laboratory and echocardiographic variab-
les in current studies are summarized in Table 12.
8.2 Can we use any intravenous iron
preparation in iron deficiency? Is B12/folate 
supplement necessary?
Various IV iron preparations are available for the 
treatment of iron deficiency including ferric carboxy-
maltose, ferric-hydroxide sucrose, ferric gluconate, 
ferumoxytol, iron isomaltoside and ferric-hydroxide 
dextran. Two IV iron preparations have mainly been 
investigated in studies on the treatment of iron defici-
ency in patients with HF: 1) ferric-hydroxide sucrose 
(alone or in combination with erythropoiesis-stimula-
previous European guidelines and other guidelines, 
the topic was discussed as iron deficiency instead of 
anemia.[6] The recommendation is quite clear and iron 
treatment is recommended regardless from anemia:
- Treatment with IV ferric carboxymaltose is 
recommended in order to improve symptoms 
of HF and to improve exercise capacity and 
quality of life in the presence of iron deficiency 
(serum ferritin level <100 µg/L, or serum fer-
ritin level 100-299 µg/L with TSAT <20%) in 
patients with symptomatic HFrEF. (Class IIa, 
evidence level A).
8.0 INTRAVENOUS IRON THERAPY 
Dilek Ural
8.1 How effective are intravenous iron
preparations in iron deficiency associated
with heart failure?
The most important effect of intravenous iron pre-
parations in HF patients with iron deficiency is rela-
ted to functional capacity and improvement of NYHA 
class, 6 minute walk test and quality of life regardless 
of anemia.[29] The improvement in functional capacity 
becomes noticeable after the fourth week and conti-
nues for a relatively long period until week 52.[30] In 
a meta-analysis of five major studies investigating IV 
iron treatment, Qian et al.[81] found that hospitalization 
rates due to HF decreases significantly in the active 
treatment group (odds ratio [OR] 0.28; 95% confi-
dence interval [CI], 0.16–0.49; p<0.001). This finding 
may be important not only for the quality of life of 
HF patients but also for healthcare costs. As a matter 
of fact, studies from various countries indicate that IV 
iron treatment is a cost-effective treatment option for 
patients with HF.[89,90]
The effect of iron replacement on mortality has 
not been proven in the currently available studi-
es. Since this may be related to the limited number 
of subjects included in the studies and short period 
of follow-up, the effect on major clinical endpoints, 
mortality in particular, has been investigated in va-
rious meta-analyses. Clevenger et al.[91] investigated 
the effect of iron replacement on 1-year mortality in 
a meta-analysis of 64 controlled studies conducted in 
9004 subjects including patients with HF, and no dif-
ference was detected between the control and the acti-
ve treatment groups. In another meta-analysis of five 
randomized controlled studies evaluating only pati-
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ting agents), and 2) ferric carboxymaltose. Iron sucro-
se is approved for the treatment of chronic renal failu-
re and iron deficiency, and should be given by slow IV 
injection over 30-60 minutes up to a maximum dose 
of 200 mg, requiring a total of ~5–7 injections. Since 
it is a safe treatment, no test dose against allergic re-
actions is required before administration. Iron sucrose 
has been tested in FERRIC-HF and IRON-HF studi-
es, and improved functional capacity regardless of the 
presence of anemia (Table 13).[84,85]
However, the number of subjects included in these 
two studies were relatively limited (35 and 18, respec-
tively) and the follow-up period was short (16 weeks 
and 3 months, respectively).
Table 12. The effects of intravenous iron preparations on clinical endpoints and laboratory tests
Clinical endpoint
Mortality All-cause death Death was reported in 39 cases (4% in the treatment  
  group vs 6% in the control group) in meta-analyses, and  
  the OR for all-cause death was 0.81, 95% CI 0.42‒1.57.[81]
Hospitalization Hospitalization due to  Hospitalization due to HF was significantly reduced  
 worsening HF (OR 0.28; 95% CI 0.16‒0.49; p<0.001).[81]    
 Composite endpoint of death  Reduced by 53% with iron replacement compared to   
 and hospitalization due to HF placebo (OR 0.47; 95% CI 0.29‒0.76; p=0.002).[81]
Functional capacity NYHA class Mean class decreased by 0.54‒1.2.[58,96]
 6-minute walktest At 24 weeks in the CONFIRM-HF study, it was increased by 
  18±8 m in the FCM group, and decreased by 16±8 m in the
  placebo group (p=0.002).[30] The increase in walking distance
  is ~31 m for the active treatment group in meta-analyses.[58]
 Patient’s global assessment Significant improvement was observed in patient’s
  self-assessment.
Quality of life KCCQ score Increased by ~5.5 points in the active treatment group   
  (95% CI 2.8‒8.3, p<0.0001)[58]
 Other scorings European Quality of Life-5 dimensional (EQ-5D) score and 
  Minnesota Heart Failure and Life Questionnaire score were  
  improved by +4.1 points and ‒19 points, respectively.[58]
Endpoints in laboratory investigations
NT-proBNP  Decreased by 389 pg/mL in the active treatment group  
  compared to the control group[93]
C-reactive protein  Decreased by 5.4 mg/L in the active treatment group  
  compared to the control group[93]
Hematologic variables Hemoglobin Increased by 2.0‒5.9 g/dL compared to the control group
  after approximately 6 months of follow-up.
 Ferritin Increased by 145‒265 µg/L compared to the control group
  after approximately 6 months of follow-up.
 Transferrin saturation Increased by 6.6‒8.9% compared to the control group  
  after approximately 6 months of follow-up.
Renal functions eGFR Increased in the active treatment group compared to
  placebo (3‒12 mL/min)[96]
Echocardiographic findings  Ejection fraction Increased by 5.0% (95% CI 0.13‒9.80) on average.[96]
FCM: Ferric carboxymaltose; CI: Confidence interval; KCCQ: Kansas City Cardiomyopathy Questionnaire; HF: Heart failure; OR: Odds ratio; eGFR: Esti-
mated glomerular filtration rate.
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capacity and quality of life in symptomatic patients 
with HFrEF diagnosed with iron deficiency (serum 
ferritin <100 μg/L or serum ferritin 100–299 μg/L and 
TSAT <20%).[6]
Vitamin B12/folate deficiency should be sought as 
a potential cause of anemia in HF. In currently ava-
ilable studies, however, anemia resulting from B12/
folate deficiency has been rarely observed in the HF 
group.[97]
Besides, there is no evidence indicating reduced 
cardiovascular events with replacement.[98] In general 
practice, iron depots are rapidly consumed following 
accelerated erythropoiesis, resulting in iron deficiency 
in patients treated with supplementary B12 and fola-
te. Therefore, patients receiving supplementary B12 
and folate may be followed up for iron deficiency, and 
Ferric carboxymaltose is a polynuclear iron (III)-
hydroxide carbohydrate complex designed to resemb-
le physiologic ferritin. Advantages of this complex 
include thesuitability to be administered in higher 
doses with a single injection, ashorter time required 
for the infusion and decreased numberof infusions to 
compensate the iron gap. In addition, the initial ad-
ministration does not require a test dose for allergic 
reactions as it is free of dextran.
Evidence indicating the favorable effects of IV 
iron treatment in patients with HF are predominantly 
obtained from studies with ferric carboxymaltose 
(FAIR-HF[29] and CONFIRM-HF[92]). Among these 
preparations, ESC 2016 Heart Failure Guidelines re-
commended only ferric carboxymaltose recommen-
ded as a class I indication and level of evidence A, 
to relieve the symptoms of HF and improve exercise 
Table 13. Randomized controlled studies with ferric-hydroxide sucrose and ferric carboxymaltose in patients with 
heart failure
 Studies in patients with HF Administration Outcome
Ferric (iron III) FERRIC-HF[84] Weekly 200 mg, Ferritin, VO2, treadmill exercise duration,
hydroxide (n=35; follow-up until ferritin >500 µg/L, NYHA functional class and patient’s global
sucrose 16 weeks) followed by monthly assessment were 200 mg improved in
   patients given active treatment compared to  
   the control groups and no difference was   
   seen in adverse events. 
   Favorable effects were more markedin
   patients with anemia.
 IRON-HF (n=18;  IV 200 mg once a  Peak oxygen utilization (VO2) 
 follow-up 3 months)[85] week for 5 weeks increased in the parenteral treatment group
   compared to the oral treatment and control  
   groups.
Ferric  FAIR-HF (n=459; 200 mg IV, once Improvements were seen in NYHA
carboxymaltose follow-up 24 weeks)[29] a week functional class, 6-minute walktest and quality  
   of life assessments regardless of the
   presence of anemia in the active treatment  
   group compared to placebo. Death rates,   
   undesired events and serious adverse events  
   were similar in both study groups.
 CONFIRM-HF (n=304 Based on specific 6-minute walking distance, NYHA functional
 patients; 52 weeks)[30] dose scheme class, patient’s global assessment, quality of  
   life, fatigue score and rate of hospitalization  
   due to worsening heart failure were reduced  
   in the active treatment group regardless of  
   the presence of anemia. There was no
   difference in terms of death and adverse   
   events compared to placebo.
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iron supplement may be employed if necessary.
Blood transfusion may cause volume overload in 
patients with HF and therefore, it is not recommended 
with the exception of serious anemia (hemoglobin <7 
g/dL).
8.3 How and for how long should intravenous 
iron therapy be administered? What should be 
the target for hemoglobin and iron levels?
The total iron dose required for iron replacement is 
calculated with the Ganzoni formula:[99]
Total iron dose to be administered (mg) = Weight 
(kg) x (Normal hemoglobin – patient’s
hemoglobin) x 2.4 + 500
While the normal hemoglobin value in the formula 
may be adopted as 12 g/dL for women and 13 g/dL for 
men, a standard level of 15 g/dL for both genders may 
also be applied. Depending on the calculated differen-
ce, the deficiency may be replaced with a single injec-
tion, or may require multiple doses. The preparation 
recommended in ESC 2016 Heart Failure guidelines 
is ferric carboxymaltose, which may be administered 
by one of the two following methods:
1) Intravenous bolus injection – The maximum 
dose that can be administered as a single bolus in-
jection is 200 mg, and no more than 3 injections are 
allowed per week. The bolus injection method was 
preferred in the FAIR-HF study where weekly ferric 
carboxymaltose equivalent to 200 mg iron was admi-
nistered during the treatment period until the calcula-
ted iron deficiency was replaced. During the mainte-
nance period, the dose was repeated every four weeks 
(often starting at week 8 or 12) based on the control 
values. Treatment was interrupted when control ferri-
tin level was>800 μg/L or ferritinis between 500–800 
μg/L and TSAT >50% or hemoglobin >16 g/dL; and 
treatment was resumed for ferritin level <400 μg/L, 
TSAT <45% and hemoglobin level <16 g/L.
 2) Intravenous infusion – The maximum dose that 
can be administered as a single intravenous infusion is 
no more than 1000 mg. A single dose should not exce-
ed 15 mg/kg or the total calculated dose. The recom-
mended administration is dilution in 50 mL or 100 mL 
0.9% NaCl for 100-200 mg and 200-500 mg, respecti-
vely, for an infusion over at least 6 minutes, or a 15-mi-
nute infusion after dilution in 250 mL 0.9% NaCl if the 
iron dose to be administered is 500-1000 mg.
Iron deficiency was calculated as per the Ganzo-
ni formula also in the CONFIRM-HF study, with an 
attempt to simplify the treatment protocol by emplo-
ying a table (Table 14).[100] The initial dose was a sing-
le dose of 500-1000 mg followed by 500 mg iron ma-
intenance every 6 weeks based on ferritin and TSAT. 
Although a high dose was used, the undiluted ferric 
carboxymaltose was administered as IV bolus injecti-
ons over at least one minute.
Overall, both studies used an average of ∼1000 
mg (200–1900 mg) iron during the treatment period 
and 875 mg (200–1000 mg) through the maintenan-
ce period; and while the total median dose was 2000 
mg in FAIR-HF (dose range 200–2400 mg), the me-
dian dose over 52 weeks was 1500 mg (dose range 
500–3500 mg) in CONFIRM-HF. In more than 75% 
of the CONFIRM-HF patients, a maximum of two 
doses was sufficient to correct and maintain iron para-
meters. On the other hand, the median number of in-
jections was 6 in the FAIR-HF study. While different 
protocols are evaluated for the route of administration 
with attempts to accelerate the process and decrease 
the number of injections, one may conclude that cur-
rently the most practical method is the protocol emp-
loyed in CONFIRM-HF.
Table 14. Treatment schedule of the CONFIRM-HF study
Treatment period
Patient’s body weight <70 kg ≥70 kg All
Hemoglobin  <10 g/dL ≥10 g/dL* <10 g/dL ≥10 g/dL* >14 ve <15 g/dL
Week 0 1000 mg 1000 mg 1000 mg 1000 mg 500 mg
Week 6 500 mg None 1000 mg 500 mg None
Maintenance period
Week 12, 24, 36 500 mg (if serum ferritin <100 µg/L or serum ferritin 100–300 µg/L and TSAT <20%)
Hb: Hemoglobin; TSAT: Transferrin saturation; *Hemoglobin ≥10 g/dL and ≤14 g/dL.
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frequency of bacterial infections. Furthermore, iron 
is thought to increase free radical generation, thereby 
triggering atherosclerosis.
However, seriousadverse events associated with 
IV iron therapy are low (approximately <1%) in cli-
nical studies. Life-threatening adverse events are also 
rare (<0.02%). In studies using ferric sucrose in HF, 
the main side effect was altered taste with more rare 
side effects reported as nausea, vomiting, abdominal 
pain, diarrhea, redness, bronchospasm, fever, myal-
gia, and injection site reactions. Ferric carboxymal-
tose was often well-tolerated and no serious allergic 
reactions were observed. The adverse effects associa-
ted with this treatment were mostly mild and included 
flushing, GIS discomfort, dizziness, rash, erythema, 
and injection site reactions. No abnormalities were 
seen in laboratory tests and the most common transi-
ent asymptomatic finding was hypophosphatemia.[103]
In a meta-analysis by Avni et al.[104] which inclu-
ded 103 studies with a total of 10,390 patients rece-
iving IV iron treatment, no increase was seen regar-
ding the risk of serious adverse events with IV iron 
therapy (relative risk [RR], 1.04; 95% CI 0.93–1.17; 
I(2)=9%). Interestingly, a decreased rate of serious 
adverse events was noted in HF patients receiving IV 
iron therapy in a subgroup analysis (RR, 0.45; 95% CI 
0.29–0.70; I(2)=0%). The most common side effect 
seen with IV iron was again infusion reactions, simi-
lar to the findings mentioned above (RR 2.47; 95% CI 
1.43–4.28; I(2)=0%). Qian et al.[81] conducted a meta-
analysis on five key studies of IV iron therapy in HF 
and did not find an increased risk of cardiovascular 
events or an increased rate of infections.
In clinical studies, IV iron therapy is often admi-
nistered in outpatients although in hospital setting. 
The in-hospital stay may be up to seven hours in some 
centers with an aim to monitor patients during the in-
fusion as well as the side effects afterwards. Day-time 
treatment clinics specialized with training in this field 
may prove useful to facilitate the administration.[105] 
Furthermore, iron treatment prior to discharge is a re-
asonable approach in patients hospitalized for acute 
HF, and studies evaluating this approach are currently 
ongoing (Study to Compare Ferric Carboxymaltose 
With Placebo in Patients With Acute Heart Failure 
and Iron Deficiency [Affirm-AHF]; NCT02937454).
8.5 Can we use a combination of intravenous 
iron and erythropoietin?
The use of erythropoiesis-stimulating agents 
(ESAs) for the treatment of anemia in chronic kidney 
Currently, there is no exact consensus regarding 
the ideal treatment target. Anemia is defined as he-
moglobin levels below 12 g/dL for women and 13 g/
dL for men as per World Health Organization guideli-
nes on the diagnosis and treatment of anemia.
In the FAIR-HF study, target hemoglobin level 
was calculated as 15 g/dL utilizing the Ganzoni for-
mula, and the hemoglobin value achieved at the end 
of treatment was 13 g/dL. However, there is no tar-
get hemoglobin level specified for patients with HF, 
and high levels of hemoglobin are even considered 
as potentially hazardous. Therefore, it appears reaso-
nable to maintain hemoglobin levels ~12 g/dL based 
on the currently available data. Similarly, there is no 
clear target value for iron levels, either.[101] The target 
ferritin level was >500 ng/mL (value achieved at the 
end of treatment: 312 μg/L) in the FAIR-HF study 
and >100 µg/L or TSAT >20% if ferritin was 100–300 
µg/L in the CONFIRM-HF study. Different targets are 
selected in different studies. Taking the follow-up pe-
riod and patient’s comfort into account, the targets in 
CONFIRM-HF appear to be more applicable. Regard-
less of the target specified, maintenance of these valu-
es should be checked by repeated tests every 3 months.
8.4 What are the possible side effects of
intravenous iron administration? Can we
administer IV iron in outpatient setting?
Historically, the side effect which required most at-
tention during parenteral iron administration has been 
anaphylactic reaction. While this side effect has been 
reported more commonly with the high-molecular 
weight iron dextran, which is rarely used today, pa-
tients should be monitored during the administration 
and through the following 30 minutes as allergic reac-
tions are reported with all IV iron preparations. There 
is no need to employ premedication for anaphylactic 
reactions. Headache is the most common side effect 
which occurs during the early phase of IV administ-
ration with all IV iron preparations. Other early phase 
reactions are reported rarely and include hypotensi-
on, muscle cramps, diarrhea, urticaria, fever, nausea, 
vomiting, hypertension, and chest pain. Lymphade-
nopathy, myalgia, arthralgia and fever may occur du-
ring the late phase. The concerns raised with IV iron 
administration in HF patients are rather different.[102]
Theoretically, overloaded iron -particularly when nor-
mal iron reservoirs are full- may deposit in tissues and 
organs, resulting in adverse biological outcomes. Be-
cause iron is a vital compound for bacteria, iron rep-
lacement is often assumed to potentially increase the 
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disease has led to considering this approach also for 
the anemia in HF.
Initially, studies were conducted with a limited 
number of patients, and the meta-analysis of these 
studies demonstrated prolonged duration of exertion 
as well as improvements in the 6-minute walking dis-
tance, with improved NYHA class and quality of life.
[106] Furthermore, a decrease was observed in hospita-
lization due to HF and all-cause mortality. The lack of 
increased adverse events was deemed encouraging to 
conduct randomized controlled trials with larger num-
ber of patients. However, no improvement was obser-
ved in clinical outcomes among a total of 2,600 HFrEF 
patients with hemoglobin levels 9–12 g/dL, while 
thromboembolic events were increased in the RED-
HF study evaluating darbepoetin alfa, a recombinant 
human erythropoietin.[63] Recent meta-analysis inclu-
ding the RED-HF study have demonstrated improved 
symptoms and functional capacity with ESA treatment, 
together with improved quality of life and decreased 
rate of hospitalization due to HF although an increased 
risk of thromboembolic events was noted during the 
safety analysis (RR 1.28, 95% CI 1.03-1.58, p=0.026).
[107,108] No increase was observed in terms of serious 
thromboembolic events. Taking current evidence and 
high costs into account, ESA treatment is not recom-
mended for the routine treatment of patients with HF.[6]
Other studies have also demonstrated an increased 
rate of thromboembolic events with ESA treatment. 
The TREAT study (n=4038) evaluating long-term use 
of darbepoetin-alfa in diabetic patients with anemia 
and chronic renal impairment[109] showed a two-fold 
increase in stroke risk, which led USA Food and Drug 
Administration (FDA) to issue a warning on chronic 
renal impairment in 2011 and recommend individual 
dose adjustment if hemoglobin levels are below 10 g/
dL and to initiate treatment with the lowest ESA dose. 
Findings of this study were consistent with RED-HF.
There is a relatively complex association between 
erythropoietin and HF. In studies indicating a link bet-
ween increased erythropoietin and poor prognosis in 
HF, patients with high levels of erythropoietin are often 
more anemic.[110] This suggests a peripheral resistance 
to the effect of endogenous erythropoietin. Pathoge-
nesis of erythropoietin resistance involves iron defi-
ciency, chronic renal impairment, acute and chronic 
inflammation, cytokines and bone marrow dysfunc-
tion. Studies have attempted to explain the increased 
risk of thromboembolic events with increased number 
thrombocytes and increased thrombopoietin activity. 
Both of these conditions are associated with iron defi-
ciency and tend to decrease in dialysis patients recei-
ving IV iron.[111] The fact that baseline erythropoietin 
levels and post-treatment thrombocyte counts are unk-
nown for the patients in RED-HF as well as those in 
the TREAT study, and the use of oral preparations for 
iron replacement (with parenteral iron used more com-
monly in the placebo group of TREAT) make it more 
difficult to evaluate the mechanism of the thrombotic 
effect. It is not possible to draw any conclusions for 
subjects with baseline hemoglobin levels <9 g/dL as 
they were excluded in the RED-HF study. There is no 
consensus regarding the target hemoglobin levels in 
HF. No difference is seen between ESA and control 
groups unless hemoglobin values exceed 12 g/dL. The 
use of fixed and high-dose darbepoetin alfa based on 
baseline hematocrit values in studies is another aspect 
of criticism.[112] Therefore, it is warranted to establish 
optimal hemoglobin levels in HF and to better specify 
which patients may experience benefit or harm with 
ESA treatment. When ESA treatment is deemed neces-
sary in HF patients with anemia, iron reservoirs should 
be screened with laboratory tests and iron replacement 
should be provided in line with applicable guidelines 
in the event of iron deficiency.
9.0 OTHER TREATMENT APPROACHES 
Dilek Yeşilbursa
9.1 Is oral iron therapy appropriate for the
treatment of iron deficiency?
European HF guidelines 2016 recommend iron the-
rapy in HF patients with iron deficiency regardless of 
the presence or absence of anemia. Oral iron therapy 
is commonly employed owing to low costs and safety. 
However, intestinal iron absorption is low in HF. The 
oral iron used in treatment is often a ferrous salt such 
as ferrous sulfate (Fe [II]). The oxidation of Fe [II] to 
Fe [III] causes oxidative damage on mucosa and this 
local toxicity results in GIS side effects, which are seen 
in 60% of the patients. Side effects in the form of cons-
tipation, dyspepsia, nausea, diarrhea and heartburn are 
more commonly seen with ferrous sulfate and tend to 
reduce compliance to treatment. The best iron absorp-
tion occurs on empty stomach. However, absorption is 
decreased as these drugs are usually taken with food 
due to GIS side effects (Table 15). Side effects resul-
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from old erythrocytes to release into plasma and inter-
feres with the release of iron into plasma as well as pre-
venting the iron mobilization from hepatic reservoirs. 
In addition to the negative effect on iron metabolism 
and the associated hypoferrinemia, hepcidin has also 
been shown to disrupt erythropoiesis and reduce proli-
feration and life-span of erythroid precursors in vitro.
The median iron dose required for iron replacement 
is 1000 mg in HF patients with iron deficiency. The 
most commonly used oral iron preparation in iron defi-
ciency anemia is ferrous sulfate, with a bioavailability 
of 10%. The daily dose of ferrous sulfate is 100-200 
mg. In the best case scenario where the patient tolerates 
the daily dose of 200 mg, iron absorption would be 20 
mg daily, requiring 50 days to correct iron deficiency. 
In a less favorable scenario where the intestinal absorp-
tion is reduced by half in a patient with HF who can 
tolerate 100 mg iron daily, only 5% (5 mg) of the iron 
would be absorbed, requiring 200 days to correct iron 
deficiency. This period would be even longer in clinical 
practice owing to the poor compliance in HF patients 
and reasons such as treatment interruption due to GIS 
side effects. Therefore, more than 6 months is required 
to correct iron deficiency using oral iron treatment.
While several cardiologists use oral iron for the 
treatment of iron deficiency, there is no evidence to 
support oral iron therapy in HF. Randomized studies 
comparing erythropoietin with oral iron versus oral 
iron therapy alone revealed no change in the groups 
receiving oral iron alone in terms of iron parameters, 
hemoglobin level, symptom severity and exercise to-
lerance testing.[64,115,116]
Results of the IRONOUT HF study investigating 
ting from oxidative stress may be prevented by using 
an oral iron [III]-polymaltose complex.
This allows a controlled and slow release of iron. 
Furthermore, the structure of oral iron [III]-polymaltose 
complex reduces the interactions with food and concur-
rent medications. As a result, use of oral iron therapy 
appears inappropriate in subjects with disrupted ab-
sorption, in patients who cannot tolerate oral treatment 
and those with poor compliance to treatment owing to 
the unfavorable effects of oral iron therapy.
The additional factors limiting the intestinal ab-
sorption of oral iron preparations in patients with he-
art failure bring IV iron administration to forefront.
[73] One of the key reasons to prefer IV iron therapy 
is the difficulty of compliance to treatment with oral 
iron (usually 3 times a day) due to the polypharmacy 
associated with HF and comorbidities. Another rea-
son is the reduced iron absorption seen in HF owing 
to several factors such as edema in the intestinal mu-
cosa, ischemia and restricted blood flow (Table 15). 
Other causes of decreased intestinal absorption inc-
lude sympathetic nervous system activation, diabetic 
gastroparesis and use of H2 receptor blockers.
Elevated levels of hepcidin are also among the fac-
tors which limit the intestinal absorption of oral iron 
preparations (Table 15). The proinflammatory cytoki-
nes increased in HF augment the hepatic synthesis of 
hepcidin. Hepcidin is a peptide hormone and the main 
regulator of systemic iron balance which is essentially 
synthesized in the liver, found in circulation and excre-
ted by urine.[113,114] Hepcidin decreases iron absorption 
in the small intestine, interferes with the iron dischar-
ge from macrophages when macrophages extract iron 
Table 15. Reasons to not recommend oral iron therapy in heart failure
Oral iron therapy in heart failure
Intestinal absorption Low
 Reduced absorption when taken with food (due to the formulation)
 Reduced absorption when taken with other medications (e.g. phosphate binders,
 antacids, H2 receptor blockers)
 Elevated hepcidin interfering with iron absorption and release from enterocytes into circulation
 Changes in the gastrointestinal tract in heart failure, such as mucosal edema, local ischemia,  
 perfusion problems
Gastrointestinal side effects Constipation, dyspepsia, nausea, diarrhea, heartburn (more common with ferrous sulfate)
Compliance Multiple daily doses (usually 3 times a day) 
 Frequency of side effects
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the efficacy of oral iron therapy in HF patients with 
low EF were disclosed in AHA 2016. The 225 patients 
included in this study were given oral iron polysacc-
haride twice daily.
At the end of 16 weeks of the randomized, double-
blind, placebo-controlled study, no difference was 
seen in primary (exercise capacity as measured by 
peak oxygen consumption) and secondary (6-minute 
walking distance, oxygen kinetics, ventilatory effici-
ency, quality of life) endpoints.
In light of all such information, oral iron therapy is 
not recommended for the treatment of iron deficiency 
in HF with or without anemia.
9.2 Could blood transfusion be a treatment
option for anemia?
Transfusion is the only way of increasing hemog-
lobin levels and thereby tissue oxygenation rapidly. 
Blood transfusion is used as an acute treatment and 
offers only transient benefits. On the other hand, it is 
associated with several risks (immune system supp-
ression, infection risk, iron overload, HLA sensitizati-
on, etc.). Therefore, it should be reserved for hospita-
lized patients with deep anemia in order to avoid side 
effects of transfusion. It is recommended to initially 
treat the correctable factors (iron, folate and/or vita-
min B12 deficiency, etc.) which may be the underl-
ying cause of anemia in anemic patients with HF.
There is no specific hemoglobin value specified 
as a threshold for transfusion. Although the evidence 
level is low, red blood cell transfusion should usually 
be considered when hemoglobin level is <7–8 g/dL 
in asymptomatic patients or when hematocrit value is 
<30%. In symptomatic patients if the symptoms are 
related to the anemia, transfusion may be administe-
red when hemoglobin levels are <10 g/dL.
There is no large, randomized controlled trial eva-
luating the effect of transfusions given when hemog-
lobin levels are <8 g/dL or <10 g/dL in patients with 
stable or decompensated HF. A meta-analysis of 26 
observational studies and 6 studies with low evidence 
level demonstrated no improvement with the liberal 
transfusion protocol compared to the less aggressive 
transfusion protocol in terms of short-term mortality 
in heart failure patients with anemia.[117]
Transfusion is employed to increase the blood’s 
oxygen-carrier capacity and to provide improved 
oxygenation for the cells. However, the oxygen-car-
rier capacity of blood supplied from blood banks is 
known to be reduced in proportion to the length of 
storage time. This is a result of the decreased 2,3 dip-
hosphoglycerate (DPG) in the blood. Low DPG levels 
increase the oxygen affinity of hemoglobin and rest-
rict the oxygen release into tissues.
When using redblood cell transfusion in patients 
with heart failure, it is recommended to assess the 
patient’s volume status and to adjust transfusion rate 
and administer additional diuretics in order to avoid 
volume overload.
9.3 Do erythropoietin preparations play a role 
in treatment?
Erythropoietin is a glycoprotein hormone primarily 
produced in the kidney by peritubular fibroblasts. It 
is released in response to hypoxia and stimulates the 
erythroid cell proliferation essentially by preventing 
apoptosis in erythroid precursors in the bone marrow. 
Studies have shown decreased erythropoietin levels 
with renal dysfunction in one third of HF patients with 
anemia.[118] On the other hand, other studies have re-
ported severely poor clinical outcomes in patients with 
high levels of endogenous erythropoietin.[119] Further-
more, no correlation has been found between hemog-
lobin and erythropoietin levels. These findings indica-
te resistance to endogenous erythropoietin in the bone 
marrow in addition to reduced endogenous erythropo-
ietin synthesis in HF patients with anemia.[118]
Chronic kidney disease is common among pati-
ents with HF and is associated with decreased eryt-
hropoietin production in the kidneys. Renal damage 
is primarily associated with hemodynamic disorders 
and parenchymal damage. Hemodynamic changes re-
sult from the redistribution of intrarenal blood flow 
and reduced renal blood flow leading to hypoxic renal 
damage. Parenchymal damage, on the other hand, is 
associated with tubulointerstitial fibrosis, tubular loss 
and glomerulosclerosis. Both the hemodynamic and 
parenchymal disorders contribute to reduced erythro-
poietin production.[118]
Elevated levels of several proinflammatory cyto-
kines such as tumor necrosis factor-alfa and IL-6 are 
seen in patients with heart failure. Cytokines reduce 
erythropoietin synthesis in the kidney by means of 
several mediators and suppress the bone marrow res-
ponse. Among proinflammatory cytokines, IL-6 inc-
reases the hepatic synthesis of hepcidin. Hepcidin is 
a peptide hormone synthesized in the liver and is the 
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investigating darbepoetin (STAMINA-HF and RED-
HF) revealed no improvement in terms of hospitaliza-
tion or mortality (Table 16).
In STAMINA-HF, 319 patients with HF (EF 40%) 
and hemoglobin levels 9-12.5 g/dL received darbepo-
etin alfa or placebo every two weeks for 1 year with a 
target hemoglobin level of 14±1 g/dL.[64] The primary 
endpoint of the study was the change in treadmill 
exercise duration while change in NYHA class and 
quality of life were evaluated as secondary endpoints. 
All-cause mortality and HF hospitalization were also 
evaluated. Although increased hemoglobin values up 
to median 1.8 g/dL were seen with darbepoetin, no 
improvement was observed in terms of exercise dura-
tion, quality of life and NYHA class. A non-significant 
decreasing trend was seen for all-cause mortality and 
first HF hospitalization (HR 0.68; 95% CI 0.43–1.08; 
p=0.10). Other adverse effects such as hypertension 
and myocardial infarction were found to be similar 
between the two groups.
RED-HF, the largest erythropoietin study to date is 
a double-blind, randomized, placebo-controlled, mul-
ti-center study investigating darbepoetin alfa in pati-
ents with HF.[63] In this study, a total of 2278 patients 
with HF (NYHA class II-IV, EF <40%) and hemoglo-
bin levels 9-12 g/dL treated with darbepoetin alfa or 
placebo (Table 16). At 28 months of follow-up, he-
moglobin levels were observed to increase from 11.2 
g/dL to 13 g/dL in the treatment group while there was 
no change in the placebo group. No difference was 
seen between the two groups regarding the primary 
endpoint which consisted of all-cause death or first 
hospitalization (50.7% vs 49.5%, HR 1.01; 95% CI 
0.90–1.13; p=0.87). Furthermore, no benefit was no-
ted in other secondary endpoints including all-cause 
mortality, cardiovascular death, HF hospitalization 
and coronary events. On the other hand, an increa-
sed rate of thromboembolic events was observed in 
the treatment group compared to placebo (13.5% and 
10.0; p=0.01). Stroke risk was found to be higher in 
the darbepoetin alfa group (5.4% vs 3.9%).
Two meta-analyses which did not include the RED-
HF study demonstrated significant improvement in qu-
ality of life, exercise tolerance and NYHA class with 
a decreased rate of HF hospitalization among patients 
treated with erythropoietin.[106,123] Further meta-analy-
ses including RED-HF are necessary to establish the 
benefit/risk profile of treatment with erythropoietin.
main regulator of systemic iron balance. It inhibits in-
testinal iron absorption as well as iron release from 
macrophages by binding to ferroportin.
Hepcidin also suppresses erythropoietin producti-
on and causes erythropoietin resistance by suppres-
sing the proliferation of erythroid precursors in bone 
marrow. Consequently, erythropoietin insufficiency 
or bone marrow unresponsiveness despite presence of 
adequate erythropoietin occurs in anemic HF patients.
The use of erythropoiesis-stimulating agents for 
the treatment of anemia in chronic kidney disease has 
led to considering this approach also for the anemia in 
HF. Darbepoetin alfa is a recombinant human erythro-
poietin. It also contains a carbohydrate chain which 
prolongs the half-life and increases biological activity 
as well as receptor affinity.
In 2000, Silverberg et al. were the first to report 
favorable outcomes with erythropoietin and IV iron 
therapy in 26 patients with severe HF and anemia.[120] 
This retrospective study revealed improved NYHA 
class, increased EF values, reduced rates of hospita-
lization and decreased need for diuretics in patients 
treated with IV iron and erythropoietin. Similar re-
sults were reported in a randomized, open-label study 
conducted by the same investigators 1 year later.[121] 
Palazzuoli et al. reported increased hemoglobin va-
lues and improved NYHA class as well as favorable 
effects on EF, exercise capacity and BNP levels with 
erythropoietin treatment.[122] While increased hemog-
lobin levels and improved quality of life were obser-
ved in a randomized, placebo-controlled study with 
darbepoetin, no difference was seen in terms of peak 
oxygen consumption, exercise duration, BNP and re-
nal functions (Table 16).
Although favorable outcomes were reported, the-
se study results are not broadly applicable owing to 
the limited number of patients enrolled in the studies. 
Furthermore, these small-scale randomized studies 
have not evaluated hard clinical outcomes such as all-
cause mortality as primary endpoints. Limitations of 
these studies include limited sample size, short durati-
on and lack of double-blind design. The double-blind, 
placebo-controlled study by van Veldhuisen et al. 
found moderately increased hemoglobin levels with 
darbepoetin treatment in 165 anemic HF patients; ho-
wever, no change was seen in quality of life, NYHA 
class and exercise capacity parameters.[116] Two large, 
multi-center, double blind, placebo-controlled studies 
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Table 16. Studies on erythropoiesis-stimulating agents in heart failure patients with anemia
Mancini
et al., 2003
Palazzuoli
et al., 2007
Ponilkowski 
et al., 2007
Van
Veldhuisen 
2007
Ghali et al.,
2008
STAMİNA-
HeFT
Swedberg 
et al., 2013 
RED-HF
LV: Left ventricle; EF: Ejection fraction; Hb: Hemoglobin; 6-MWD: Six-minute walking distance; HF: Heart failure; MI: Myocardial infarction; Cr: Creatinine, 
PGA: Patient’s Global Assessment score.
Single-center, 
randomized, 
single-blind
Single-center, 
randomized, 
double-blind
Multi-center, 
randomized, 
double-blind
Multi-center, 
randomized, 
double-blind
Multi-center, 
randomized, 
double-blind
Multi-center, 
randomized, 
double-blind
Epoetin
alfa/placebo
Epopoetin 
beta/placebo
Darbepoetin 
alfa/placebo
Darbopoetin 
alfa/placebo
Darbopoetin 
alfa/placebo
Darbopoetin 
alfa/placebo
3
12
6
6
12
28
Exercise capacity, 
vasodilator function
Primary: LV
dimensions, LVEF, Hb, 
Cr, BNP Secondary: 
Cardiac event (sudden 
death, hospitalization, 
MI), weight, edema, 
NYHA class
Primary: Exercise 
capacity Secondary: 
Change in peak VO2, 
exercise capacity, Hb, 
NYHA class, quality 
of life, BNP, weight, 
hospitalization
Primary: Increase in 
Hb, Secondary: LVEF, 
6-MWT, NYHA, quality 
of life, PGA
Primary: Change in 
exercise tolerance 
Secondary: NYHA, 
quality of life, time to 
death, first
hospitalization due
to HF
Primary: All-cause
mortality or first hospi-
talization due to HF 
Secondary: Death from 
cardiovascular cause 
or first hospitalization 
due to HF, MI, stroke, 
hospitalization due 
to HF, sudden death, 
quality of life
Increase in 6-MWD and 
peak oxygen
consumption with 
increased Hb levels
Decrease in LV size, 
volume and mass; 
increased EF;
reduction in PAP and 
BNP; decreased hospi-
talization, increased Hb 
in the EPO group
No difference between 
the groups in terms of 
VO2, exercise duration, 
BNP and renal function
Non-significant between 
the two groups in terms 
of 6-MWD (p=0.074) 
and PGA (p=0.057)
No significant
improvement in
exercise duration, 
NYHA and quality of 
life with darbepoetin 
compared to placebo
No significant dif-
ference in primary 
endpoints between the 
two groups. 
Increased rate of 
thromboembolic events 
in the treatment group.
Yes
Yes
Yes
Yes
Yes
Yes
Study Study Design ESA / control Follow-up 
(months)
Endpoint ResultIronN
Silverberg
et al., 2000
Silverberg
et al., 2001
Single-center, 
randomized, 
open-label
Epo
Epoetin alfa
7±5
8.2
NYHA class, LVEF,
decrease diuretics 
dose, hospitalization
NYHA class, LVEF,
decrease diuretics 
dose, hospitalization 
Improvement in NYHA 
class, increased EF, 
decrease in hospitaliza-
tion rates and reduced 
need for diuretics
Improvement in NYHA 
class with increased Hb 
levels, increase in EF, 
decreased hospitaliza-
tion rates and reduced 
need for diuretics
Yes 
(IV)
Yes
(IV)
26
32
23
51
41
165
319
2278
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The second method employs serum transferrin le-
vels which enable iron transfer in the plasma while cal-
culating the TSAT value (Serum iron/Serum transferrin 
x 70.9).[124] Serum transferrin is a protein which decrea-
ses with malnutrition and chronic disease. Therefore, it 
tends to be elevated in chronic inflammation and chro-
nic diseases where serum iron levels remain unchan-
ged. This value may also demonstrate fluctuations.[125]
Taken together, serum ferritin and TSAT may pro-
vide incorrect results and mask iron deficiency particu-
larly in the presence of chronic disease, inflammation 
and infection. This risk may be even more misleading 
with the standalone iron deficiency which develops 
without anemia, representing increasingly more signi-
ficance from the current clinical perspective.
Studies show that a TSAT value below 20% pro-
vides a good indicator of iron deficiency.[48] However, 
there is no definite “cut-off” value for ferritin. Some 
studies indicate that iron deficiency cannot be ruled 
out when ferritin levels are below 100 ng/mL or even 
200 µg/L.[126,127]
In recent years, the “soluble” transferrin receptor 
(sTfR) has become another test utilized for the diag-
nosis of iron deficiency owing to its early and high 
sensitivity.[128] The transferrin receptor is a membrane 
protein which allows internalization of iron into the 
cell. During this internalization process, some of the 
TfRs are shed into circulation, which may be measu-
red as sTfR.[129] Elevated sTfR levels are seen in iron 
deficiency and these elevated levels are not influenced 
by chronic disease, infection or inflammation. Owing 
to this advantage, sTfR may be a more accurate test 
especially in the presence of chronic disease anemia or 
in patients with infection and inflammation (Table 17). 
However, it should be noted that false decreases may 
be seen with this value in the event of malnutrition or 
atransferrinemia.[130] Generally, in microcytic anemias 
with MCV below 75 fL, sTfR level assay is recom-
mended for the differential diagnosis between iron de-
ficiency and anemias secondary to chronic inflammati-
on or chronic disease anemia. The fact that this is a new 
test associated with high costs and difficulty in standar-
dization poses a barrier regarding its widespread use as 
a standard method. One may expect to see this test in 
standard practice during the years to come.[130]
Iron staining of bone marrow biopsy material re-
mains the method with the highest level of accuracy 
in showing iron deficiency and iron reservoirs. 
The differences between the studies may be par-
tially explained by the different protocols employed, 
different doses of erythropoietin and different grades 
of anemia.
Vast majority of anemic HF patients have concur-
rent renal dysfunction. Currently, erythropoietin is 
recommended for the treatment of anemia in patients 
with chronic kidney disease. Could it also be used in 
anemic HF patients with renal dysfunction? Diffe-
rent doses and routes of administration (oral iron vs. 
IV iron) used for iron treatment with erythropoietin 
in different studies may notably affect the outcomes 
(owing to the defective oral iron absorption in pati-
ents with heart failure). Atrial fibrillation and hyper-
tension often co-exist with HF. These conditions may 
increase the rate of embolic events. The hemoglobin 
level to initiate treatment with erythropoietin has been 
specified as 11.5 g/dL in large studies. This hemoglo-
bin level may not be an appropriate target to initiate 
erythropoietin treatment. The darbepoetin dose used 
in studies may be high. Further studies are warranted 
to find out the answer to all these questions (optimal 
hemoglobin target for intervention, clinical characte-
ristics of the patients, comorbidities to avoid erythro-
poietin treatment).
However, current guidelines do not recommend 
the use of erythropoietin preparations for the treat-
ment of anemia in HF.
10.0 CONSIDERATIONS FROM THE
HEMATOLOGICAL POINT OF VIEW 
Mustafa Çetiner
10.1 How reliable are ferritin and transferrin 
saturation as criteria for iron deficiency
diagnosis?
While serum ferritin levels and TSAT are the most 
commonly utilized and most accurate tests for the di-
agnosis of iron deficiency, they are limited in terms of 
definitive diagnostic values. Serum ferritin is an acute 
phase reactant which increases in the presence of inf-
lammation. Also, ferritin levels are known to potenti-
ally differ between males and females. Similar condi-
tions also apply to TSAT. TSAT is calculated by two 
different methods in practice. The first method defines 
TSAT as the serum iron:iron binding capacity ratio. 
(TSAT = (Serum iron/Total iron binding capacity) × 
100). This is the commonly utilized method. 
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10.2 How is the differential diagnosis
established in iron deficiency and anemia
versus other anemias?
Taking into account the fact that patients with he-
art failure are often elderly, the anemia seen in these 
patients may result from various causes. Evaluating 
the parameters presented in Table 17 is important for 
the differential diagnosis of iron deficiency anemia 
and other anemias.[131] Low hemoglobin level is one 
of the parameters which have direct effects on life ex-
pectancy in patients over the age of sixty five years. 
Studies show increased frequency and length of hos-
pitalization as well as higher mortality rates in older 
anemic patients.[132] Therefore, it is essential to probe 
and treat anemia in the elderly.
Chronic disease anemia, chronic inflammation, 
chronic infections, myelodysplastic syndrome-like bone 
marrow failure syndromes, hematological cancers, bone 
marrow involvement of non-hematological cancers, 
drug effects, deficiency of other essential components 
such as vitamin B12 and folic acid should also be taken 
into account as well as iron deficiency when conside-
ring the causes of anemia. Hematology consultation is 
recommended for patients for whom anemia etiology 
cannot be adequately clarified with standard tests.
10.3 How safe is intravenous iron therapy?
Could it cause toxic effects?
Intravenous iron therapies have remained as treat-
ments used with concern owing to the serious risk of 
anaphylaxis associated with IV iron preparations con-
taining dextran.[133,134] Therefore, dextran-containing 
molecules are not preferred in the current practice whi-
le preparations which do not contain dextran such as 
iron sucrose and iron carboxymaltose are used instead.
Risk of allergic reaction is the most important side 
effect to discuss regarding the drugs in this group. Tra-
ditionally, using anti-histamines prior to IV iron admi-
nistration has been a widely adopted approach. Howe-
ver, this approach is in fact not recommended. Contrary 
to the popular belief, diphenhydramine and similar 
agents used for this purpose mildly increase the risk of 
allergic reactions and infusion reactions, and also lead 
to a greater risk of nasal congestion, wheezing and sup-
raventricular tachycardia.[135] Premedication should not 
be used except for patients with history of drug allergy 
or asthma, and these patients should be given 125 mg 
methylprednisolone prior to administration.[135]
As stated above, anaphylaxis is the most important 
side effect associated with IV iron therapy. Hypersen-
sitivity risks of IV iron preparations are presented in 
Table 18.[136,137]
There is also a reaction referred to as Fishbane reac-
tion which may be confused with hypersensitivity reac-
tions following the administration of intravenous iron 
treatment.[138] This reaction is characterized by mild 
chest and back pain, arthralgia, and myalgia. The key 
Table 17. Tests which may be used for the differential diagnosis of iron deficiency anemia
Test Iron deficiency anemia Chronic disease anemia Iron deficiency anemia + chronic disease anemia
Ferritin Low High Normal / high
TIBC High Low Normal / high
SI Low Low Low 
sTfR High Normal High
TIBC: Total iron binding capacity; SI: Serum iron; sTfR: Soluble transferrin receptor.
Table 18. Frequency of life-threatening drug reactions with IV iron preparations
 Risk in one million individuals
High-molecular weight dextran 11.3
Low-molecular weight dextran 3.3
Iron gluconate (not available in Turkey) 0.9
Iron sucrose 0.6
Iron carboxymaltose A similar risk has been observed in comparative studies with iron sucrose[137]
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increase with the use of IV iron agents. While GIS side 
effects were significantly low with IV preparations, al-
lergic reactions were increased although no death was 
reported in these patients.[104]
The fact that bacteria and other infectious agents 
require iron as a growth factor and the increased frequ-
ency of infections in patients diagnosed with hereditary 
hemochromatosis with increased iron load[142] suggest 
a link between IV iron load and frequency of infecti-
ons. However, no such link has been demonstrated in 
studies.
Nausea, vomiting, and diarrhea may occur in pa-
tients receiving treatment with IV iron, although at a 
much lower rate compared to those receiving oral iron 
therapies. Tinnitus, headache, pruritus, rash, and urti-
caria may also occur. The likelihood varies from 6% to 
10% for each of these symptoms. Only nausea occurs 
with an incidence of 10-15% and is highlighted as the 
most common side effect. All of these side effects are 
temporary.[143]
Iron overload is observed very rarely and does not 
occur with standard treatments.
feature of this presentation is the absence of tachycar-
dia and hypotension.
In fact, hypotension, tachycardia, bronchoconstric-
tion, stridor, and periorbital edema may be observed 
with true hypersensitivity reactions. Fishbane reaction 
does not require medical intervention and the presen-
tation resolves spontaneously within minutes. As the 
anxiety the patient or the physician may experience 
during this period may hinder completing the administ-
ration, the team in charge of IV iron treatment should 
be informed about Fishbane reaction.
The report on IV iron administration issued by 
EMA in 2013[139] has clearly identified the principles to 
be followed during the administration. These principles 
are summarized in Table 19.
Conditions associated with an increased frequency 
of allergic reactions are well-documented.[140] These 
risk groups are presented in Table 20.
In fact, a very low risk of hypersensitivity is repor-
ted in clinical studies, particularly with non-dextran 
containing preparations. This risk is not higher than 
it is with any other drug. The total risk of hypersensi-
tivity reaction development was found to be 24-68 in 
one hundred thousand individuals through 688,183 IV 
iron administrations.[141]
A meta-analysis evaluating the data from one hund-
red and three studies has compared the use of oral iron 
and placebo, and did not find any side effects which 
Table 19. Principles to follow during IV iron 
administration
A test dose for IV preparations is neither necessary nor 
recommended by EMA and FDA. 
Patients should remain under monitoring for at least 30 
minutes after the administration. Hypersensitivity
reactions often occur during or within half an hour after 
the administration.
IV administration must not be performed in subjects with 
history of hypersensitivity reaction during IV iron treatment. 
The administration should be employed with caution in 
patients with known allergy (drug allergy), serious atopy, 
systemic inflammatory response, rheumatoid arthritis or 
any other systemic inflammatory disease.
The administration should be performed by an experienced 
team and in a setting where interventions are readily available.
Table 20. IV demir uygulaması sırasında aşırı duyarlılık 
riskinin arttığı durumlar
Rapid administration*
Subjects with history of drug reaction or hypersensitivity 
reaction 
Subjects with serious asthma or eczema
Mastocytosis
Subjects with serious respiratory or cardiac condition**
Patients receiving ACE inhibitors or beta blockers**
Pregnancy (first trimester)***
Subjects with systemic inflammatory conditions (systemic 
inflammatory response, rheumatoid arthritis)
Intense anxiety experienced by the relevant healthcare 
professional, physician or patient***
*Rapid administration is often discouraged. However, this is not the case 
for carboxymaltose. IV carboxymaltose administration should not exceed 
20-30 minutes and the fluid volume should be no more than 250 mL.
Prolonged administration and over-dilution impair the drug’s stability and 
increase the risk of reactions.
**Rapid decompensation may be observed following Fishbane-type reac-
tions in this group of patients and clinical symptoms may present with a 
rapid and more dramatic prognosis due to limited organ capacity.
***Administration during the first trimester is not common due to the lack 
of sufficient clinical data.
****Intense anxiety may trigger Fishbane-type reactions. A potential hyper-
sensitivity reaction may worsen the clinical presentation and complicate 
the management.
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FCM: Ferric carboxymaltose; Hb: Hemoglobin; TSAT: Transferrin saturation
1Iron deficiency diagnosis is irrespective of anemia. Iron deficiency diagnosis in heart failure should be based on the criteria specified in the algorithm 
provided above. On the other hand, it should be taken into account that ferritin values <30 µg/L and transferrin saturation <20% are required for the 
definitive diagnosis of classic iron deficiency. However, because ferritin is an acute phase reactant, iron deficiency cannot be ruled out with levels of 
30–100 µg/L. In recent years, where available, transferrin receptor-1 (TfR-1) level has been used for the diagnosis of iron deficiency as a marker which 
is not influenced by infection or inflammation. Ferritin index (TfR-1/log ferritin) <1 translates into a diagnosis of iron deficiency.
2Treatment decision is independent from anemia. In practice, the iron to be administered as 500 mg or 1000 mg is recommended to be given as an 
infusion >15 minutes after dilution in 250 mL of 0.9% NaCl. Although iron was administered as intravenous bolus >1 minute without reconstitution in the 
CONFIRM-HF study, intravenous bolus administration is associated with a risk of necrosis due to potential extravasation and therefore the consensus 
algorithm herein recommends administering iron as infusion after dilution.
3There is no evidence on the benefit of continued iron therapy after 36 weeks.
*Iron therapy is not recommended when Hb >15 g/dL as efficacy and safety have not been established.
Symptomatic HFrEF
Diagnosis and treatment of iron deficiency in chronic heart failure
No Anemia or Iron Deficiency
Hb: Men >13 g/dL, Women >12 g/dL
Ferritin >100 µg/L and TSAT >20%
Repeat the tests: 
NYHA I/II ‒ Once a year 
NYHA III/IV ‒ Every 6 
months
Consider other causes
of anemia 
Hematology Consultation
IV iron (preferably FCM)2
CONFIRM-HF Protocol[30]
Treatment Period
Maintenance Period
Target: Ferritin ≥100 µg/L and TSAT ≥20%
Repeat the tests: Every 3 months
Hb <7 g/dL – Transfusion
Hb ≥7 g/dL – Cause-directed treatment
Weight
All
Week 0
Week 6
<70 kg
<10 g/dL >14 - <15 g/dL*≥10 g/dL<10 g/dL
1000 mg 500 mg1000 mg
500 mg (if serum ferritin <100 µg/L or serum ferritin 100–300 µg/L 
and TSAT <20%)
1000 mg1000 mg
500 mg Yok500 mg1000 mgYok
All≥70 kg
Week 12,
24, 363
Anemia (no Iron Deficiency)
Hb: Men <13 g/dL, Hb: Women <12 g/dL
Ferritin >100 µg/L and TSAT >20%
Anemic or Non-anemic Iron Deficiency1
Ferritin <100 µg/L or 
Ferritin 100‒299 µg/L and TSAT <20%
Complete blood count
Serum ferritin, TSAT
11.0 CONSENSUS ALGORITHM
≥10 g/dL
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